trends in
NEUROSCIENCES

Author Index

Subject Index

Index of Books Reviewed

2000

Volume 23
Issues 1–12

ISSN 0166-2236

ELSEVIER
SCIENCE
LONDON

Trends in Neurosciences

Elsevier Science London,
84 Theobald's Road,
London, UK WC1X 8RR
Tel: +44 (0)20 7611 4400
Fax: +44 (0)20 7611 4401
E-mail: tins@current-trends.com

Advisory Editorial Board

A. Björklund *Lund, Sweden*
S.W. Bottjer *Los Angeles, CA, USA*
J.M. Bower *Pasadena, CA, USA*
M. Burrows *Cambridge, UK*
C.Q. Doe *Eugene, OR, USA*
A.C. Dolphin *London, UK*
C.R. Gerfen *Bethesda, MD, USA*
P.S. Katz *Atlanta, GA, USA*
H.O. Kettenmann *Berlin-Buch, Germany*
R. Malenka *Stanford, CA, USA*
J. Mallet *Paris, France*
M. Mattson *Baltimore, MD, USA*
R.G.M. Morris *Edinburgh, UK*
S. Nakanishi *Kyoto, Japan*
V.H. Perry *Southampton, UK*
S. Redman *Canberra, Australia*
N. Rothwell *Manchester, UK*
W. Singer *Frankfurt, Germany*
H. Steller *Cambridge, MA, USA*
M.T. Tessier-Lavigne *San Francisco, CA, USA*
C. Walsh *Boston, MA, USA*
S.P. Wise *Bethesda, MD, USA*

Editors Sîan Lewis, Gavin Swanson

Assistant Editor Caroline Jones

Editorial Administrators Sebastian Kokelaar, Laura Stagnell

Production Helen Budd, Jane Tozer

Publishing Manager Robert Brines

© 2001 Elsevier Science Ltd.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science London, 84 Theobald's Road, London, UK WC1X 8RR.

Author Index

BR – Book Review
L – Letter

A

Absher, J.R., see Vogt, B.A. (L) 195
Acebes, A. and Ferrús, A., Cellular and molecular features of axon collaterals and dendrites 557
Acuña, C., see Grieve, K.L. 35
Akerman, C.J., see Rawlins, N. 280
Alho, K., see Kujala, T. 115
Allsopp, T.E., Hunting the arbiters of neurodegeneration 385
Allsopp, T.E. and Fazakerley, J.K., Altruistic cell suicide and the specialized case of the virus-infected nervous system 284
Allsopp, T.E. and Fazakerley, J.K., Reply (L) 468
Allsopp, T.E. and Fazakerley, J.K., Reply (L) 611
Andolina, I., see Rawlins, N. 280
Ango, F., see Fagni, L. 80
Archelos, J.J. and Hartung, H-P., Pathogenetic role of autoantibodies in neurological diseases 317

B

Bähr, M., Live and let die – retinal ganglion cell death and survival during development and in the lesioned adult CNS 483
Baker, M.D., Axonal flip-flops and oscillators 514
Ball, G.F., see Balthazart, J. (L) 57
Balthazart, J. and Ball, G.F., Fast regulation of steroid biosynthesis: a further piece in the neurosteroid puzzle (L) 57
Bar, I., Lambert de Rouvroit, C. and Goffinet, A.M., The evolution of cortical development. An hypothesis based on the role of the Reelin signalling pathway 633
Barger, S.W., see Mattson, M.P. (L) 466
Beal, M.F., Energetics in the pathogenesis of neurodegenerative diseases 298
Begbie, J., see Graham, A. 313
Ben-Ari, Y. and Cossart, R., Kainate, a double agent that generates seizures: two decades of progress 580
Bernardi, G., see Calabresi, P. 120
Berrendero, F., see Fernández-Ruiz, J. 14
Betz, H., see Kneussel, M. 429
Biessels, G-J., see Gispen, W. H. 542
Bjaalie, J.G. and Leergaard, T.B., Functions of the pontine nuclei in cerebro-cerebellar communication (L) 152
Blake, D.J. and Kroger, S., The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? 92
Blakemore, S-J., see Rawlins, N. 280
Blasko, I., see Grubeck-Loebenstein, B. (L) 114
Bockaert, J., see Fagni, L. 80
Boncinelli, E., see Cecchi, C. 347
Bravin, M., see Strata, P. (L) 198
Brenowitz, E.A., see Tramontin, A.D. 251
Brevig, T., Holgersson, J. and Widner, H., Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them 337
Brown, R.G. and Pluck, G., Negative symptoms: the 'pathology' of motivation and goal-directed behaviour 412
Brussaard, A.B. and Herbison, A.E., Long-term plasticity of postsynaptic GABA(A) receptor function in the adult brain: insight from the oxytocin neuron 190
Bunin, M.A., see Wightman, R. (L) 59
Bush, G., see Vogt, B.A. (L) 195

C

Cadet, P., see Stefano, G.B. 436
Calabresi, P., Centonze, D., Gubellini, P., Pisani, A. and Bernardi, G., Acetylcholine-mediated modulation of striatal function 120
Capaday, C., Control of a 'simple' stretch reflex in humans (L) 528
Carlen, P.L., see Perez Velazquez, J.L. 68
Casares, F., see Stefano, G.B. 436
Cattaert, D., see Clarac, F. (L) 529
Cattaert, D., see Clarac, F. 199
Caviness, Jr, V.S., see Gilmore, E.C. 100
Caviness, Jr, V.S., see Gilmore, E.C. (L) 408
Cecchi, C. and Boncinelli, E., Emx homeogenes and mouse brain development 347
Centonze, D., see Calabresi, P. 120
Cha, J-H.J., Transcriptional dysregulation in Huntington's Disease 387
Chalupa, L.M., see Cook, J.E. 26
Chan, S.L., see Mattson, M.P. 222
Chavis, P., see Fagni, L. 80
Chopp, M., see Cramer, S.C. 265
Christie, G., see Howlett, D.R. 565
Chun, J., Cell death, DNA breaks and possible rearrangements: an alternative view (L) 407
Clarac, F. and Cattaert, D., Reply (L) 529
Clarac, F., Cattaert, D. and Le Ray, D., Central control components of a 'simple' stretch reflex 199
Clements, J.D. and Silver, R.A., Unveiling synaptic plasticity: a new graphical and analytical approach 105
Cook, J.E. and Chalupa, L.M., Retinal mosaics: new insights into an old concept 26
Cossart, R., see Ben-Ari, Y. 580
Cramer, S.C. and Chopp, M., Recovery capitulates ontogeny 265
Cudeiro, J., see Grieve, K.L. 35

D

Dantzer, R., see Kelly, K.W. (L) 467
Dantzer, R., see Venters, H.D. 175
Davidson, C., see Stamford, J.A. 459
Day, R., see Salzet, M. 550
De Keyser, J., Sulter, G. and Luiten, P.G., Reply (L) 246
de la Rosa, E.J. and de Pablo, F., Cell death in early neural development: beyond the neurotrophic theory 454
de Pablo, F., see de la Rosa, E.J. 454
de Wied, D., Peptide hormones and neuropeptides: birds of a feather (L) 113
Derkach, V.A., see Soderling, T.R. 75
Deuchars, J., Does the head rule the heart? 449
Deuchars, J., Nerves – the silent but strong type 333
Di Marzo, V., see Szallasi, A. 491
Dingwall, C., see Howlett, D.R. 565
Dragunow, M., see Walton, M.R. 48
Dudel, J., see Parnas, H. 60
Duncan, J. and Owen, A.M., Common regions of the human frontal lobe recruited by diverse cognitive demands 475
Duysens, J., Reply (L) 529

E

Egelman, D.M., see King, R.D. (L) 12
Emerich, D.F., Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? (L) 245
Everitt, B., Robbins, T., Groenewegen, H. and Lopez-Silva, F., Amygdala-striatal interactions 231
Eysel, U.T., see Worgotter, F. 497

F

Fagni, L., Chavis, P., Ango, F. and Bockaert, J., Complex interactions between metabotropic glutamate receptors, intracellular calcium stores and ionic channels in neurons 80
Fazakerley, J.K., see Allsopp, T.E. (L) 468
Fazakerley, J.K., see Allsopp, T.E. 284
Fazakerley, J.K., see Allsopp, T.E. (L) 611
Fekete, D., Ear rings: FGF3 involvement comes full circle 332
Fekete, D.M., Making sense of making hair cells 386
Fernández-Ruiz, J., Berrendero, F., Hernández, M.L. and Ramos, J.A., The endogenous cannabinoid system and brain development 14
Ferrús, A., see Acebes, A. 557
Ficchione, G.L., see Stefano, G.B. 436
Fields, R.D. and Stevens, B., ATP: an extracellular signaling molecule between neurons and glia 625
Flavell, R.A., see Kuan, C-Y. 291
Frade, J.M., NRAGE and the cycling side of the neurotrophin receptor p75 591
Fudge, J., see Parkinson, J. 383
Fujikawa, D.G., Confusion between neuronal apoptosis and activation of programmed cell death mechanisms in acute necrotic insults (L) 410

G

Geiger, N., see Mattson, M.P. 222
Gerber, U., see Heuss, C. 469
Gerlai, R., Down to less than 300 genes: The DNA sequence of human chromosome 21 and Down's Syndrome 332
Gerlai, R., Protein targeting: altering receptor kinase function in the brain 236
Gerlai, R.T., Genotype x environment interaction: an old problem in a new field 450
Gilmore, E.C., Nowakowski, R.S., Caviness, Jr, V.S. and Herrup, K., Cell birth, cell death, cell diversity and DNA breaks: how do they all fit together? 100
Gilmore, E.C., Nowakowski, R.S., Caviness, Jr, V.S. and Herrup, K., Reply (L) 408
Gingrich, M.B. and Traynelis, S.F., Serine proteases and brain damage – is there a link? 399
Gispen, W.H. and Biessels, G-J., Cognition and synaptic plasticity in diabetes mellitus 542
Gleeson, J.G. and Walsh, C., Neuronal migration disorders: from genetic diseases to developmental mechanisms 352
Glickstein, M., How are visual areas of the brain connected to motor areas for the sensory guidance of movement? 613
Glorioso, J., see Simonato, M. 183
Goffinet, A.M., see Bar, I. 633
Gokhan, S., see Mehler, M.F. 599
Goumon, Y., see Stefano, G.B. 436
Graham, A. and Begbie, J., Neurogenic placodes: a common front 313
Grieve, K.L., Acuña, C. and Cudeiro, J., The primate pulvinar nuclei: vision and action 35
Groenewegen, H., see Everitt, B. 231
Grubeck-Loebenstein, B., Blasko, I., Marx, F. and Trieb, K., Immunization with β-amyloid: could T-cell activation have a harmful effect? (L) 114
Gubellini, P., see Calabresi, P. 120
Guillery, R.W., Early electron microscopic observations of synaptic structures in the cerebral cortex: a view of the contributions made by George Gray (1924–1999) 594
Gurwitz, D., New imaging techniques for early diagnosis of Alzheimer's disease 386
Guthrie, S., Ephrin cleavage: a missing link in axon guidance 592

H

Haas, K., Prefabrication provides synapses on demand 449
Hackney, C.M., Active forces in hearing 233
Halpain, S., Actin and the agile spine: how and why do dendritic spines dance? 141
Harteneck, C., Plant, T.D. and Schultz, G., From worm to man: three subfamilies of TRP channels 159
Hartung, H-P., see Archelos, J.J. 317
Herbison, A.E., see Brussaard, A.B. 190
Hernandez, M., Nieto, M.L. and Sanchez Crespo, M., Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells 259
Hernández, M.L., see Fernández-Ruiz, J. 14
Herrup, K., see Gilmore, E.C. (L) 408
Herrup, K., see Gilmore, E.C. 100
Heuss, C. and Gerber, U., G protein-independent signaling by G-protein-coupled receptors 469
Holgersson, J., see Brevig, T. 337
Holsboer, F., see Rupprecht, R. (L) 58
Hopwood, S.E., see Stamford, J.A. 459
Howlett, D.R., Simmons, D.L., Dingwall, C. and Christie, G., In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase 565
Hurd, Y., see Parkinson, J. 383
Hutcheon, B. and Yarom, Y., Resonance, oscillation and the intrinsic frequency preferences of neurons 216

I

Israel, M., Ladislav Tauc 1926–1999 47
Iversen, L.L., Reply (L) 114
Iwaniuk, A.N. and Whishaw, I.Q., On the origin of skilled forelimb movements 372

J

Jakel, R.J. and Maragos, W.F., Neuronal cell death in Huntington's disease: a potential role for dopamine 239
Johnsen, S., see Lohmann, K.J. 153

K

Kasai, H., Corrigendum to 'Comparative biology of CA^{2+}-dependent exocytosis: implication of kinetic diversity for secretory function', *TINS* 22, 2 43
Kastin, A.J., What is a neuropeptide? (L) 113
Kay, A.R., see White, J.A. 131
Kelley, K.W., see Venters, H.D 175
Kelly, K.W., Venters, H.D. and Dantzer, R., Reply (L) 467
Keynes, R., Kirik, D. and Nieto-Sampedro, M., European neuroscience meets the snow 91
Kilduff, T.S. and Peyron, C., The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders 359
Kilduff, T.S., Narcolepsy: a neurodegenerative disease of the hypocretin/orexin system? 512
King, R.D., Wiest, M.C., Montague, P.R. and Egelman, D.M., Do extracellular calcium signals carry information through neural tissue? (L) 12
Kirik, D., see Keynes, R. 91
Kneussel, M. and Betz, H., Clustering of inhibitory neurotransmitter receptors at developing postsynaptic sites: the membrane activation model 429
Korkotian, E., see Segal, M. (L) 198
Korkotian, E., see Segal, M. 53
Krakauer, D.C., Evolving cell death in the virus-infected nervous system (L) 611
Kroger, S., see Blake, D.J. 92
Kuan, C-Y., Roth, K.A., Flavell, R.A. and Rakic, P., Mechanism of programmed cell death in the developing brain 291
Kujala, T., Alho, K. and Näätänen, R., Cross-modal reorganization of human cortical functions 115
Kullmann, D.M., see Rusakov, D.A. (L) 13

L
LaFerla, F., see Mattson, M.P. 222
Lambert de Rouvroit, C., see Bar, I. 633
Lamme, V.A.F. and Roelfsema, P.R., The distinct modes of vision offered by feedforward and recurrent processing 571
Le Ray, D., see Clarac, F. 199
Lederhendler, I. and Schulkin, J., Behavioral neuroscience: challenges for the era of molecular biology 451
Leergaard, T.B., see Bjaalie, J.G. (L) 152
Leissring, M.A., see Mattson, M.P. 222
Lewis, S., Editorial 509
Lohmann, K.J. and Johnsen, S., The neurobiology of magnetoreception in vertebrate animals 153
Lopez-Silva, F., see Everitt, B. 231
Lowenstein, P.R., Un pour tous, tous pour un (L) 467
Luheshi, G.N., see Rothwell, N.J. 618
Luiten, P.G., see De Keyser, J. (L) 246

M
Maddock, R.J., Reply (L) 196
Magnussen, S., Low-level memory processes in vision 247
Maleszka, R., Molecules to behaviour in the honeybee – the emergence of comparative neurogenomics 513
Malicki, J., Harnessing the power of forward genetics – analysis of neuronal diversity and patterning in the zebrafish retina 531
Manservigi, R., see Simonato, M. 183
Maragos, W.F., see Jakel, R.J. 239
Marconi, P., see Simonato, M. 183
Maren, S., Reply (L) 345
Marx, F., see Grubeck-Loebenstein, B. (L) 114
Mattson, M., Turning off the anxiety master switch 333
Mattson, M.P. and Barger, S.W., Silencing survival data (L) 466
Mattson, M.P., Creatine: prescription for bad genes and a hostile environment? 511
Mattson, M.P., LaFerla, F., Chan, S.L., Leissring, M.A., Shepel, P.N. and Geiger, J.D., Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders 222
McCollum, G., Social barriers to a theoretical neuroscience 334
McKinnon, P.J., see Rolig, R.L. 417
McLaughlin, D.P., see Stamford, J.A. 459
Medina, L. and Reiner, A., Do birds possess homologues of mammalian primary visual, somatosensory and motor cortices? 1
Mehler, M.F. and Gokhan, S., Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat 599
Meyer-Rochow, V.B., Visual membrane vulnerability: the fatty-acid connection (L) 13
Montague, P.R., see King, R.D. (L) 12
Morando, L., see Strata, P. (L) 198
Mrisc-Flogel, T., see Rawlins, N. 280
Murphy, D.D., see Segal, M. (L) 198
Murphy, D.D., see Segal, M. 53
Murray, E.A., see Wise, S.P. 271

N
Näätänen, R., see Kujala, T. 115
Nicholls, D.G. and Ward, M.W., Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts 166
Nieto, M.L., see Hernandez, M. 259
Nieto-Sampedro, M., see Keynes, R. 91
North, R.A., Potassium-channel closure taken to TASK 234
Nowakowski, R.S., see Gilmore, E.C. (L) 408
Nowakowski, R.S., see Gilmore, E.C. 100

O
Owen, A.M., see Duncan, J. 475

P
Parkinson, J., Fudge, J., Hurd, Y., Pennartz, C. and Peoples, L., Finding motivation at Seabrook Island: the ventral striatum, learning and plasticity 383
Parnas, H., Segel, L., Dudel, J. and Parnas, I., Autoreceptors, membrane potential and the regulation of transmitter release 60
Parnas, I., see Parnas, H. 60
Parnavelas, J.G., The origin and migration of cortical neurons: new vistas 126
Pennartz, C., see Parkinson, J. 383
Peoples, L., see Parkinson, J. 383
Perez Velazquez, J.L. and Carlen, P.L., Gap junctions, synchrony and seizures 68
Peyron, C., see Kilduff, T.S. 359
Piccolino, M., The bicentennial of Voltaic battery (1800–2000): the artificial electric organ 147
Pisani, A., see Calabresi, P. 120
Plant, T.D., see Harteneck, C. 159
Pluck, G., see Brown, R.G. 412
Poo, M-M., see Schinder, A.F. 639
Privat, A., see Ridet, J.L. (L) 58

R
Rakic, P., see Kuan, C-Y. 291
Ramos, J.A., see Fernández-Ruiz, J. 14
Rawlins, N., Akerman, C.J., Andolina, I., Blakemore, S-J. and Mrisc-Flogel, T., Four year PhDs in neuroscience: an assessment after four years 280
Reiner, A., see Medina, L. 1
Rice, M.E., Ascorbate regulation and its neuroprotective role in the brain 209
Ridet, J.L. and Privat, A., Volume transmission (L) 58
Robbins, T., see Everitt, B. 231
Roelfsema, P.R., see Lamme, V.A.F. 571
Rogawski, M.A., KCNQ2/KCNQ3 potassium channels and the molecular pathogenesis of epilepsy: implications for therapy 393
Rolig, R.L. and McKinnon, P.J., Linking DNA and neurodegeneration 417
Rossi, F., see Strata, P. (L) 198
Roth, K.A., see Kuan, C-Y. 291
Rothwell, N.J. and Luheshi, G.N., Interleukin 1 in the brain: biology, pathology and therapeutic target 618
Roy, M. and Sapolsky, R.M., Reply (L) 411
Rubinstein, J.T., see White, J.A. 131
Rupprecht, R. and Holsboer, F., Reply to Balthazart and Ball (L) 58
Rusakov, D.A., Kullmann, D.M. and Stewart, M.G., Reply to King, Montague *et al.* (L) 13

S
Salzet, M., Vieau, D. and Day, R., Crosstalk between nervous and immune systems through the animal kingdom: focus on opioids 550
Sanchez Crespo, M., see Hernandez, M. 259
Sapolsky, R.M., see Roy, M. (L) 411
Schinder, A.F. and Poo, M-M., The neurotrophin hypothesis for synaptic plasticity 639
Schulkin, J., see Lederhendler, I. 451
Schultz, G., see Harteneck, C. 159
Schwarz, C. and Thier, P., Reply (L) 152
Segal, M., Korkotian, E. and Murphy, D.D., Dendritic spine formation and pruning – common cellular mechanisms? 53
Segal, M., Korkotian, E. and Murphy, D.D., Reply (L) 198
Segel, L., see Parnas, H. 60
Sensi, S.L., see Weiss, J.H. 365
Shepel, P.N., see Mattson, M.P. 222
Silver, R.A., see Clements, J.D. 105
Simmons, D.L, see Howlett, D.R. 565
Simonato, M., Manservigi, R., Marconi, P. and Glorioso, J., Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors 183
Soderling, T.R. and Derkach, V.A., Postsynaptic protein phosphorylation and LTP 75
Spier, A., Za Zdorovie! 385
Spier, A.D., Are we what we dream? 511
Stamford, J.A., Davidson, C., McLaughlin, D.P. and Hopwood, S.E., Control of dorsal raphé 5-HT function by multiple 5-HT1 autoreceptors: parallel purposes or pointless plurality? 459
Stefano, G.B., Goumon, Y., Casares, F., Cadet, P. and Ficchione, G.L., Endogenous morphine 436

Stevens, B., see Fields, R.D. 625
Stewart, M.G., see Rusakov, D.A. (L) 13
Strata, P., Morando, L., Bravin, M. and Rossi, F., Dendritic spine density in Purkinje cells (L) 198
Sulter, G., see De Keyser, J. (L) 246
Svendsen, C., Adult versus embryonic stem cells: which is the way forward? 450
Swanson, G.J., Editorial 331
Swanson, G.J., Editorial 509
Swanson, L.W., What is the brain? 519
Syed, S., Neuroscion – a meeting of minds 279
Szallasi, A. and Di Marzo, V., New perspectives on enigmatic vanilloid receptors 491

T

Thier, P., see Schwarz, C. (L) 152
Thomson, A.M., Facilitation, augmentation and potentiation at central synapses 305
Tramontin, A.D. and Brenowitz, E.A., Seasonal plasticity in the adult brain 251
Traynelis, S.F., see Gingrich, M.B. 399
Trieb, K., see Grubeck-Loebenstein, B. (L) 114

U

Ulfig, N., The ganglionic eminence – new vistas (L) 530

V

van Hooft, J.A. and Vijverberg, H.P.M., 5-HT3 receptors and neurotransmitter release in the CNS: a nerve ending story? 605
Vazdarjanova, A., Does the basolateral amygdala store memories for emotional events? (L) 345
Venters, H.D., Dantzer, R. and Kelley, K.W., A new concept in neurodegeneration: TNF-α is a silencer of survival signals 175
Venters, H.D., see Kelly, K.W. (L) 467
Vieau, D., see Salzet, M. 550
Vijverberg, H.P.M., see van Hooft, J.A. 605
Vogt, B.A., Absher, J.R. and Bush, G., Human retrosplenial cortex: where is it and is it involved in emotion? (L) 195

W

Walsh, C., see Gleeson, J.G. 352
Walton, M.R. and Dragunow, M., Is CREB a key to neuronal survival? 48
Wang, K.K.W., Calpain and caspase: can you tell the difference? 20
Wang, K.K.W., Corrigendum: Calpain and caspase: can you tell the difference? 59
Ward, M.W., see Nicholls, D.G. 166
Weiss, J.H. and Sensi, S.L., Ca^{2+}–Zn^{2+} permeable AMPA or kainate receptors: possible key factors in selective neurodegeneration 365
Whishaw, I.Q., see Iwaniuk, A.N. 372
White, J.A., Rubinstein, J.T. and Kay, A.R., Channel noise in neurons 131
Widner, H., see Brevig, T. 337
Wiest, M.C., see King, R.D. (L) 12
Wightman, R. and Bunin, M.A. , Reply (L) 59
Wise, S.P. and Murray, E.A., Arbitrary associations between antecedents and actions 271
Worgotter, F. and Eysel, U.T., Context, state and the receptive fields of striatal cortex cells 497

Y

Yarom, Y., see Hutcheon, B. 216
Yoo, S.H., Coupling of the IP_3 receptor/Ca^{2+} channel with Ca^{2+} storage proteins chromogranins A and B in secretory granules 424

Subject Index

Indexer: Dr Laurence Errington

BR – Book Review L – Letter
O – Obituary

Abbreviations used: ER, endoplasmic reticulum; Glu, glutamate.

A

Accessory protein and IL-1 receptor, 620
Acetylcholine
  5-HT_3 receptors and release of, 608
  striatal, 120–126
Acetylcholine receptors, muscarinic, *see* Muscarinic ACh receptors
Actin
  axonal branching and, 559
  dendritic spines and, 141–146
Action, pulvinar nuclei and, 37–38
Action potential, Ca^{2+} currents and, 305–306
ADAM family, 566
Addiction, drug
  gene transfer studies, 186–188
  opiate, 440–441
Adeno-associated virus (AAV) for neuronal gene transfer, 183–184, 188–189
Adenosine receptors, 631
Adenovirus for neuronal gene transfer, 183–184, 188
ADP-ribosyltransferase as caspase substrate, 23
Advanced glycation products in diabetes, 546, 547
Afferent axons, *see* Sensory neurones
Affiliative behaviour, 452
After-potential, depolarizing, 515
Ageing brain, diabetes, 546–547
Akt, 601
Alcohol and pregnancy, 40–41(BR)
Allopregnanolone, 138(BR)
Alphaviruses and neural cell suicide, 286–288
Alzheimer's disease, 446–447(BR), 623
  amyloid-ß and its precursor, *see* Amyloid-ß; Amyloid precursor protein
  animal models, 506(BR)
  diabetes and, 548
  diagnosis, new imaging techniques, 386
  ER-mediated Ca^{2+} signalling and, 226, 227
  excitotoxic injury and, 366
  familial early-onset (FAD), 601, 603
  IL-1 and, 622, 623
  methods and protocols, 446–447(BR)
  mitochondrial dysfunction, 302
  vitamin C and E and, 302
Amacrine cells and retinal mosaics, 30–31
Amino acids, excitatory, *see* Excitatory amino acids
Amniotes
  cortical evolution, 633–638
  telencephalon, *see* Telencephalon
cAMP response element binding protein, *see* CREB
AMPA receptors
  Ca^{2+}–Zn^{2+} permeable, and selective neurodegeneration, 365–371
  diabetes and, 545
  phosphorylation and modulation of, and early-phase LTP, 76–78
Amphetamine abuse and genes and environment, 450
Amphibian, hearing, 377–378(BR)
Amygdala
  basolateral complex of, memory and emotions and, 345–346(L)
  extended, 384
  5-HT_3 receptors, 607–608
  pain and, gene transfer studies, 188
Amyloid-β, 446–447(BR)
  excitotoxic injury and, 366
  plaques, imaging in Alzheimer's disease, 386
  precursor, *see* Amyloid precursor protein
  as therapeutic target in Alzheimer's disease, 114(L)
Amyloid precursor protein, 446(BR)
  as caspase or calpain substrate, 23–24
  β-secretase processing, 565–570
Amyotrophic lateral sclerosis (ALS), 365
  excitotoxic injury in, 366
  IL-1 and, 622
  mitochondrial dysfunction, 301
Analgesia
  novel aspects, 181–182(BR)
  opiates and, 181–182(BR), 437, 438–439
  psychological mechanisms, 587–588(BR)
Anandamide, 18, 493–494
  transporter, ligands, 492
  vanilloid receptors and, 493–494
Androgens and seasonal plasticity in songbirds, 255–256
Animal models of neurodegenerative disease, 506–507(BR)
Ankle extensors/flexors and stretch reflex, 528(L)
Antalarmin, 333
Anterior cingulate cortex, *see* Cingulate cortex
Antibodies in neural xenograft rejection, 339–340
  see also Autoantibodies; Monoclonal antibodies
Anticonvulsants, KCNQ2/3 K^+ channel openers as, 397
Antidepressants and dorsal raphé 5-HT receptors, 464
Antioxidant(s)
  Alzheimer's disease and, 302
  ascorbate as, 213–214
Antisense oligonucleotides, 447(BR)
  brain function altered with, 238, 447(BR)
Anxiety, 333
AP1 and ER, 225
Apaf1 (mammalian homologue of *ced-4*), 102, 295, 484, 485
Apathy, 412–414
Apis mellifera behaviour, 513–514
Aplysia, Ladislav Tauc's studies, 47(O)
ApoE receptor 2 gene (*Apoer2*), 356
Apoptosis/programmed/normal cell death (neuronal primarily), 24, 410–411(L)
  calpain in, 21–22
  caspase in, 22, 24, 102, 288
    and viral infection, 285, 287
  CREB and neuronal resistance to, 48–53
  in developing brain, 291–297, 454–458, 483–490
  diagnostic markers, 22
  DNA breaks and, 102–103, 407–409(L)
  ER-mediated Ca^{2+} signalling and, 226–227
  IL-1 and, 622
  lesion-induced, 488–489
  mitochondria in, 486–487
  necrosis vs, 410–411(L)
  in neurological/neurodegenerative disorders, 20–21
  p75 neurotrophin receptor and, 487, 501
  retinal, 32–33, 455, 456, 484–488, 591
  serine proteases and, 402
  viruses and, 284–290, 467–468(L), 611–612

Arachidonic acid (AA) astrocytoma cell transcriptional programmes, 259–264
2-Arachidonyl-glycerol, 18
Arbitrary visuomotor mapping, 271–276
Archistriatal robust nucleus of songbirds, seasonal plasticity, 252–256
Area X of songbirds, seasonal plasticity, 252–256
Areas 23 and 31 and emotion, 195–196(L)
Aristotle's model of brain CNS/brain organization, 520, 521, 522
Arm-reaching movement and pulvinar nuclei, 37
Aromatase in brain, 57(L)
Arousal, 359–365
  cortical responses, 500, 501
  orexins and hypocretins and, 359–365
Arrestins, 471
Arvanil, 492, 493
Ascorbate, *see* Vitamin C
Aspartic proteinase, amyloid precursor protein processing, 565–570
Assistance reflex interneurones, 203
Astrocytoma cell transcriptional programmes, cytosolic phospholipase A_2 and, 259–264
Ataxia
  episodic, type 1 (EA1), 395, 396
  Friedreich's, mitochondrial dysfunction, 298–299
Ataxia telangiectasia, 417–418, 422
Atlases, *see* Maps
ATM (ataxia telangiectasia, mutated), 418, 422
ATP, 277(BR)
  mitochondrial generation, 167, 171–172
  neurone–glial communication and, 625–632
Attention, 444–445(BR)
  cortical responses, 500, 502
Auditory nerve cells, channel noise, 136
Auditory placode (otic placode), 314, 315, 332
Auditory system, 233–234
  FGF3 and, 332
  fish and amphibian, 377–378(BR)
  see also Hearing
Autoantibodies, 317–326
  beneficial and regulatory effects, 322
  in neurological diseases, 317–326
Autoreceptors for neurotransmitters
  5-HT_1, 459–465
  neurotransmitter release and, 60–68
Avian neuroscience, *see* Birds
Axons
  flip-flops and oscillators, 514–519
  growth and regeneration, *see* Growth; Regeneration
  terminals, George Gray's EM observations, 597

B

B cells
  autoantibodies and, 317–319, 319, 323–325
    beneficial and regulatory effects, 322
  development, 318–319
  physiology, 318–319
    CNS, 323–325
Baer's observations on brain anatomy/organization, 522
Basal ganglia and arbitrary visuomotor mapping, 271–276
Basal optic root, nucleus, pigeons, 155
Basilar membrane, 233
Bax and development in brain/CNS/retina, 293–294, 296, 484, 485
Bcl2 (and *Bcl2* family) and neuronal survival/death, 288, 484, 485–486
  CREB and, 51
  retina, 484, 485–486
  virus-encoded, 285, 286
Bcl-X_L brain development, 293–296
Becker muscular dystrophy, 92, 93
Bee behaviour, 513–514
Behaviour
  early brain disorders affecting, 504–505(BR)
  goal-directed, motivation and, 414–415
  honeybee, 513–514
  molecular studies, 451–454
  neuronal gene transfer in, 183–190
  neurocomputational studies, 378–379(BR)
Binding, motivational, 384
Bioenergetics, mitochondrial, and neurodegenerative disorders, 240, 298–304, 329(BR)
Birds
  magnetoreception, 155–157
  pallium/cortex
    development, 634, 636, 638
    and mammalian counterparts, 1–12
  song control system, seasonal changes, 251–258
Blindness, cross-modal neural reorganization, 115–120
Blood–brain barrier
  immunity and, 337–338
    autoantibodies, 321, 323–324
  serine proteases and, 401
Bloom syndrome, 421
BNDF, *see* Brain-derived neurotrophic factor
Bobolink, magnetoreception, 156, 157
Brain, 96
  apoptosis, *see* Apoptosis
  ascorbate in, 209–216
  behavioural effects of early disorders/damage, 504–505(BR)
  clotting/fibrinolytic system, 400
  consciousness and, 229–230(BR), 648–650(BR)
  development, *see* Development
  in diabetes, 542–549
  dual, model, 520, 521–524
  in Duchenne muscular dystrophy, 96
  function, 93
  dystrophin family in, 96
  IL-1 in, *see* Interleukin-1
  as immune privileged recipient organ, 337–338
  injury
    ATP release in, 630–632
    creatine and, 511
    excitotoxic, *see* Excitotoxicity
    neuronal survival following, CREB and, 48–53
  mind and, 229–230(BR)
  in muscular dystrophy, *see* Muscular dystrophy
  neurocomputational studies, *see* Computational studies
  organization/architecture, part/present models, 519–527
  PLA_2 in, pathophysiological role, 260
  plasticity, *see* Plasticity
  proteases and the, 20–26, 399–407
  protein targeting studies of function, 236–239
  segmental model, 520–521, 522–523, 524
  sexual differentiation, 507(BR)
  vanilloid receptor distribution, 494
  see also Blood–brain barrier; Central nervous system
Brain cell communication, reticulum theory, 68
Brain-derived neurotrophic factor
  bird song seasonal changes and, 253, 255
  cell death and
    in development, 487
    in lesioned adult CNS, 488
  CREB phosphorylation and, 50
  lesioned adult CNS and, 488–489
  multiple sclerosis and, 322
  in stroke recovery, 269
  synaptic plasticity and, 639–645
Brainstem, efferent fibres from cerebral cortex targeting, 615

C

CA1 pyramidal neurones/CA1 region
  kainate and seizures and, 580–587
  LTP in, *see* Hippocampus
CA3 pyramidal cells
  G-protein-independent signalling by G-protein-coupled receptors, 469, 472
  kainate and seizures and, 580–587
Caenorhabditis elegans
  apoptosis, 291
  transient receptor potential channels, 160, 161, 163, 164, 165
CAG repeat and Huntington's disease, 387
  see also Polyglutamine-containing proteins; Trinucleotide repeat diseases

Caged-Ca^{2+} compounds, studies of Ca^{2+}-dependent exocytosis, 43
Cajal, Ramón y, 230(BR), 231(BR)
Cajal–Retzius cells and cortical development, 128, 349, 356
Calcium ion(s)
AMPA and kainate receptors permeable to, selective neurodegeneration and, 365–371
axonal branching and, 560–561
central synapse function and, 305–312
crustacean eye and, 13–14(L)
dendritic spine morphology and, 53–57
exocytosis and, 43(*erratum*)
LTD and LTP and, *see* Long-term depression; Long-term potentiation
metabotropic Glu receptors and ion channels and intracellular stores of, 80–88
mitochondrial, excitotoxicity and, 167, 172
neurotransmitter release and role of, 60–68, 305–312
signalling, 12–13(L)
in endoplasmic reticulum, 222–229
storage proteins (chromogranins), IP_3 receptors and, 424–428
Calcium ion/calmodulin-dependent protein kinases (CAMKs)
calmodulin-dependent protein kinase IV as caspase or calpain substrate, 23
CAMKII and early-phase LTP, 76–78
Calcium ion channels
L-type, ryanodine receptors and metabotropic Glu receptors and, 81–83
TRP (transient receptor potential), 159–160, 161
Calcium ion currents, striatal, 121–122
Calcium ion-dependent protein kinases and early-phase LTP, 76–78
Calmodulin-dependent protein kinases, *see* Calcium ion/calmodulin-dependent protein kinases
Calpain, 20–26
caspase 3 and, *see* Caspase
Calpastatin as caspase or calpain substrate, 24
Calsenilin, 226
Cannabinoids, 14–20
endogenous, 492–493
brain development and, 14–20
receptors
ligands, 492
ontogeny, 16
Capsaicin receptor, vanilloid subtype, *see* Vanilloid receptor
Cardiac tissue, *see* Heart
Caretaker genes, 421
Caspases, 20–26, 102, 288
caspase 3 and calpains
common or related substrates, 22–24
comparing/contrasting properties, 21
in development (mammals)
brain/CNS, 291–297, 484–485, 487
retina, 484–485
Huntington's disease and, 385, 388, 389
viral infection and, 285, 287
CD4/CD8 T cells and neural xenograft rejection, 341
Cdk5, 356–357, 357
ced, 291, 484–486
ced-3, 484–485
ced-4 and its mammalian homologue (*Apaf-1*), 102, 295, 484, 485
ced-9, 485–486
Cell(s)
brain, reticulum theory of communication between, 68
motility, actin and, 142–144, 144–145
Central nervous system
ascorbate in, 209–216
autoimmune disorders, 320
B cells in, 323–325
cell death and survival, *see* Death; Survival
development, *see* Development
Duchenne muscular dystrophy and, 92–99
5-HT_3 receptors and neurotransmitter release in CNS, 605–610
in muscular dystrophy, *see* Muscular dystrophy
neurodegeneration, *see* Neurodegeneration
nomenclature/organization, historical development, 519–527
paracrine neurotransmission, 58–59(L)
regeneration, 91
repair, 59(L), 337–344
xenotransplantation, immunological barriers, 337–343
Cerebellum
behavioural effects of early disorders/damage, 504(BR)
cerebral cortex and, pontine nuclei as interface between, 152–153(L)
neurone mosaics (non-random arrays), 27
visuomotor connections in the sensory guidance of movement and, 616–677
Cerebral cortex, *see* Cortical areas
Cerebral ischaemia and ascorbate, 213–214
Cerebrospinal fluid, ascorbate levels, 209
Channel noise, 131–137
Channelopathies, *see* Ion channels
Charcot–Marie–Tooth disease 385
noise, 131–137
Chemical magnetoreception, 154–156
Childhood
behavioural effects of early brain disorders, 504–505(BR)
cross-modal neural reorganization after, 117–118
Cholecystokinin release and 5-HT_3 receptors, 608
Cholinergic amacrine cells and retinal mosaics, 30–31
Cholinergic system, striatal, 120–126
see also Muscarinic ACh receptors
Chordotonal organ at coxo-basipodite joint, crayfish, 200–207
Chromogranins and IP_3 receptors, 424–428
Chromosome 21 DNA sequence and Down's syndrome, 332
Cingulate cortex (posterior and anterior)
emotion and, 195–197(L)
pain and, 588
Clotting system, brain, 400
Coagulation system, brain, 400
Cocaine abuse, gene transfer studies, 186–188
Cochlea, 233–234
implants, enhancing performance, 136
Cockayne syndrome, 420
Co-enzyme Q_{10} use in mitochondrial disorders, 302
Cognition
deficits
dendritic spine dysgenesis and, 141
diabetes and, 542–549
Duchenne muscular dystrophy and, 93, 96
frontal lobe areas activated by different cognitive demands, 475–483
neurocomputational studies, 378–379(BR)
sex differences, 138(BR)
Collybistin, 431–432
Colour vision, 589
Compound eye and fatty acids, 13–14
Computational studies, 443–444(BR)
of brain pathology, 378–379(BR)
Conditional motor learning/conditional discrimination, 271–276
Conditioning and amygdala, 345(L)
Cones
nerve growth, and axonal branching, 557–564
retinal, patterning (in development), 28–30, 31–32
Congenital muscular dystrophy, 97
Connexin, 628
Consciousness, 229–230(BR), 648–650(BR)
Convulsions, *see* Seizures
Copper–zinc superoxide dismutase and amyotrophic lateral sclerosis, 301
Cortical areas/cortex, cerebral (pallium)
avian, and mammalian counterparts, 1–12
cerebellum and, pontine nuclei as interface between, 152–153(L)
cross-modal reorganization of function, 115–120

development
Emx homeogenes and, 347–352
evolution, 633–638
neuronal, *see subheading below*
double cortex and double cortin (DCX), 353–354, 357
negative symptoms and apathy and, 413, 415
neurones, development, 126–131, 530(L)
disorders, 352–359
pontine nuclei and
pontine nuclei as interface between cerebellum and cortex, 152–153(L)
pontine nuclei as target for efferent fibres from cortex, 615
representing body regions, plasticity in stroke recovery, 266–267, 269
synapses, George Gray's EM observations of structure, 594–598
visual responses, 571, 573
see also specific parts of cerebral cortex
Cortical plate (CP) in development, 126–130, 347, 352, 633–638
reeler mouse, 349–350, 355
Corticofugal system and tangentially migrating neurones, 129
Cortico–thalamo–cortical loops, 38–39
Corticotrophin-releasing factor and anxiety/stress, 333
Coxo-basipodite chordotonal organ, crayfish, 200–207
Cranial sensory system development, neurogenic placodes and, 313–316
Crayfish
eye, polyunsaturated fatty acids and, 13–14(L)
stretch reflex and locomotor system, *see* Locomotor system; Stretch reflex
Creatine, 511
use, 511
in mitochondrial disorders, 302
CREB (cAMP-response-element-binding protein)
cocaine abuse and, 186–188
neuronal survival and, 48–53
CRH and anxiety/stress, 333
Crocodilians, cortical development, 635, 638
Crustaceans
eye, and polyunsaturated fatty acids, 13–14(L)
stretch reflex and locomotor system, *see* Locomotor system; Stretch reflex
Currents in neurones
amplifying, 219–220
resonant, 219
Cyclic AMP response element binding protein (CREBP) and neuronal survival, 48–53
Cyclin-dependent kinase-5 (Cdk5), 356–357, 357
Cyclo-oxygenase and TNFα, 263
Cystic fibrosis transmembrane conductance regulator, 628
Cytochrome c and apoptosis, 486–487
Cytokines, 618–624
neuropathology, 175–180, 466–467(L), 619–621, 621, 622
Cytoplasmic complex (of dystrophin-associated protein complex), 94, 95, 96
Cytoskeleton
of dendritic spines, actin-based, 142, 143
neuronal migration and, 352–359

D

D-23129 (retigabine), 397
Dab-1, 356, 357, 637
Danio rerio, retinal neurogenesis, 531–541
DCX (doublecortin), 353–354, 357
Deafness, perceptual advantage or disadvantage in information processing, 118
Deafness-dystonia, 300
Death, neural/neuronal, 91, 166–180, 239–245, 284–297, 399–407, 407–409(L), 454–458, 466–468(L), 483–490
in development, 291–297, 454–458, 483–490
DNA breaks and, 102–103, 407–409(L)
excitotoxic, *see* Excitotoxicity
IL-1 and, 621–622
necrotic, *see* Necrosis
in neurodegenerative disease, *see* Neurodegeneration
p75 neurotrophin receptor and, 487, 501
programmed, *see* Apoptosis
proteases and, 20–26, 399–407
TNFα and, 175–180, 466–467(L)
viruses and, 284–290, 467–468(L), 611–612(L)
see also Survival
Death receptors and their ligands, 288
virus-encoded, 285
Degeneration, *see* Neurodegeneration
Dementias and diabetes, 548
Demyelinating diseases and axonal oscillations, 517–518
see also Multiple sclerosis
Dendrites, 41(BR), 230(BR), 645–647(BR)
branching/collaterals, 557–565, 646(BR)
Ca^{2+} signalling and, 12–13(L)
in Purkinje cells, density, 198(L)
of songbird robust nucleus, seasonal growth, 254
spines, 198(L)
actin-filament dynamics, 141–146
regulator of morphology, 53–57
Dentate granule cells after brain injury, CREB as resistance to, 48–49, 51
Dependence, opiate, 440–441
Depolarization
mitochondrial
ATP and, 167
Ca^{2+} and, 167, 172
neurotransmitter release and, 60–68
primary afferent, presynaptic inhibition produced by, 201–203
Depolarizing after-potential, 515
Depression (affective disorder) and antidepressants and dorsal raphé 5-HT receptors, 464
Depression (synaptic), long-term, *see* Long-term depression
Descending pathways of spinal cord and skilled forebrain movement, 372–376
Deubiquitinating enzyme mutant, 603–604
Development
brain/CNS (in general)
alcohol and, 14–20
apoptosis and, 291–297, 454–458, 483–490
cortex, *see* Cortical areas
DNA breaks during, 100–105
Emx homeogenes and, 347–352
endocannabinoids and, 14–20
neurodegenerative disease and defects in, 599–604
stroke recovery recapitulating, 265
cranial sensory, neurogenic placodes and, 313–316
neural crest in, 445–446(BR)
neuronal
cortical, *see* Cortical areas
DNA recombination during, 100–105
retina, *see* Retina
retinal cell death in, 32–33, 455, 456, 484–488, 591
see also Neurogenesis
Developmental (embryological) model of CNS organization, 521, 522, 524–525
DFF45 (DNA fragmentation factor-45), 293
Diabetes and cognition and synaptic plasticity, 542–549
Diacylglycerol
striatal projection neurones and, 123
transient receptor potential channels and, 162–163
Disabled 1 (Dab1), 356, 357, 637
Dizziness and vertigo, 40(BR)
Dlx1/2, 128
DNA breaks, 407–409(L)
in developing CNS, 100–105
repair, 101
DNA damage and neurodegeneration, 417–424
DNA fragmentation factor-45, 293
Dolichonyx oryzivorus (bobolink), magnetoreception, 156, 157
Dopamine
honeybee behaviour and, 513
5-HT_3 receptors and release of, 608

Huntington's disease and, 239–245
Parkinson's disease and, 188
ventral striatum and, 383–384
Dorsal raphé 5-HT function, 459
Dorsal root ganglion and axon–Schwann cell signalling, 629
Dorsal stream visual areas and sensory guidance of movement, 614–615, 615–616
Dorsal vagus nucleus, 449
Dorsal ventricular ridge in cortical evolution, 634
Double cortex and doublecortin (DCX), 353–354, 357
Down's syndrome and chromosome 21 DNA sequence, 332
Dreaming and REM sleep, 140(BR), 362–364, 511
Drosophila transient receptor potential channels, 160–161, 162, 163
Drug abuse (substance abuse), 440–441
genes and, 186–188
environment and, 450
Drug-associated learning, 384
Drug-associated plasticity, 384
Dual brain model, 520, 521–524
Duchenne muscular dystrophy, 92–99
Dystonias, mitochondrial dysfunction, 300
Dystrobrevin, 95, 96
Dystroglycan, 94, 95, 96, 97
Dystrophin, 93, 95, 96–97
retinal distribution, 97, 98
Dystrophin-associated protein complex (DPC), 93–98
retinal distribution, 97, 98

E

Ear
FGF3 and otic vesicles, 332
frog, 377(BR)
hair cells, 386
Eaton–Lambert myasthenic (LEMS) syndrome, 317, 319, 320, 321, 323
Ectopic discharges, peripheral nerves, 514–519
Effector functions of autoantibodies in nervous system, 319–321
Efferent fibres from cerebral cortex targeting brainstem, 615
Electric organs, artificial, Volta and, 147–151
Electrical channel noise, 131–137
Electromagnetic induction, fish, 154
Electron microscopy, synapses in cerebral cortex, George Gray's observations, 594–598
Electrophysiological experiments of A Volta, 149–151
Electrotonic interactions, neuronal synchrony through, 68–74
Elsevier's Encyclopedia of Neuroscience, 139–140(BR)
Embryological (developmental) model of CNS organization, 521, 522, 524–525
Embryology, molecular, methods/protocols, 380–381(BR)
Emotions
amygdala and memory of, 345–346(L)
retrosplenial cortex and, 195–197(L)
Emx homeogenes and mouse brain development, 347–352
Encephalitis, Rasmussen's (RE), 320, 321
Encephalopathies
diabetic, 542–549
transmissible spongiform, 182(BR)
Endocannabinoids, *see* Cannabinoids
Endocrine–nervous system interactions, 329–330(BR)
Endoplasmic reticulum, Ca^{2+} signalling, 222–229
Energetics, mitochondrial, and neurodegenerative disorders, 240, 298–304, 329(BR)
Enkephalins and immunity, 552–553
Ephrins, 592
targeting with immunoadhesins, 236–237, 239
Epibranchial placode, 314, 315
Epilepsy
IL-1 and, 622
KCNQ K^+ channels and, 393–398
temporal lobe, *see* Temporal lobe epilepsy
see also Seizures
Epileptogenesis and neuronal synchrony, 68–74
Episodic ataxia type 1 (EA1), 395, 396
Episodic memory, *see* Memory
Ethanol and ethanol abuse in pregnancy, 40–41(BR)
European Neurosciences, FENS 1st winter school, 91–92
Evolution
CNS organization, 525–526
of cortical development, 633–638
language, 276
neocortex (mammals) and Wulst (avian pallium), independent, 3–7
neural crest in, 445–446(BR)
neuroimmune processes, 550–555
skilled forebrain movement, 372–376
Excitatory amino acids
ACh and striatal release of, 123
transporters, glutamate–ascorbate heteroexchange and, 211
see also Excitotoxicity
Excitatory pyramidal cells (cerebral cortex), origin/migration, 126–131
Excitotoxicity/excitotoxic cell death
AMPA and kainate receptors and selective neurodegeneration and, 365–371
ER-mediated Ca^{2+} signalling and, 226–227
Huntington's disease and, 240, 241
mitochondria and, *see* Mitochondria
serine proteases and, 404–405
see also Excitatory amino acids
Exocytosis
autoreceptors and, 64–65
Ca^{2+}-dependent, 43(*erratum*)
Experimental models of neurodegenerative disease, 506–507(BR)
Extracellular space/fluid
ascorbate in, 209–211
Ca^{2+} movement through, 12–13(L)
Eye
compound, fatty acids and, 13–14
movement, pulvinar nuclei and, 37
see also Ophthalmic placode; Retina

F

FAK as caspase or calpain substrate, 23
Fanconi anaemia, 420–421
Fatty acids and compound eyes, 13–14(L)
Fear and amygdala, 345–346(L)
Federation of European Neurosciences, 1st winter school, 91–92
Feedforward processing in vision, 571–579
Fetus
alcohol effects, 40–41(BR)
cannabinoid effects, 15
cell culture studies, 18
FGF3 and otic vesicles, 332
Fibrinolytic system, brain, 400
Fibroblast growth factor-3 and otic vesicles, 332
Filamin-1 (FLN1), 353, 357
Firing patterns, neuronal, synchronization, 68–74
Fish
electromagnetic induction, 154
hearing, 377–378(BR)
FLN1, 353, 357
Fluctuation-analysis techniques with synapses, 105
Focal-adhesion kinase as caspase or calpain substrate, 23
α-Fodrin as calpain and caspase substrate, 22
Forebrain (proencephalon; prosencephalon)
5-HT function, 459–465
development, *Emx* homeogenes and, 347–352
Forelimb movement, skilled
humans (arm), pulvinar nuclei and, 37
origin, 372–376
Frataxin, 298–299
Free radical scavenger, ascorbate as, 214
Frequency preferences of neurones, 216–222
Friedreich's ataxia, mitochondrial dysfunction, 298–299
Frontal lobe
cortex of, arbitrary visuomotor mapping and, 271–276
different cognitive demands and activation of, 475–483
Fukuyama congenital muscular dystrophy, 97
Functional neuroimaging, *see* Neuroimaging
Functional Neuroscience, 647(BR)
Fundamental Neuroscience, 41–42(BR)
Fungal prions, 182(BR)

G
G-protein-coupled receptors,
G-protein-independent signalling, 469–475
GABA
ACh and striatal release of, 123
5-HT_3 receptors and release of, 608–609
neurosteroids and, 139(BR)
presynaptic effects of kainate on release of, 583, 584
$GABA_A$-receptor, postsynaptic
clusters, formation, 429–431
plasticity, 190–195
GABARAP, 430
α-Galactosyl epitope and neural xenograft rejection, 339, 341
Galvani, Luigi, 147
Ganglion cell, retinal, in development, 32–33, 455, 456, 484–488
Ganglionic eminence, cortical interneurones derived from, 126–131, 530(L)
Gap junctions and neuronal synchrony and seizures, 68–74
Gender and cognition, 138(BR)
Gene(s)
behaviour and, 183–190, 451–454
in brain development, 504(BR)
caretaker, 421
drug abuse and, *see* Genes
epilepsy-susceptibility, 393–398
expression
CREB and, 48, 51
ER and, 225–226
see also Transcription
honeybee behaviour and, 513
in neurodegenerative disease, 599–604
mitochondrial, affecting mitochondria, 300, 301–302
nuclear, affecting mitochondria, 298–300
in neuronal migration disorders, 352–359
zebrafish, and retinal neurogenesis, 531–541
Gene targeting, 236
protein targeting as alternative to, 236–239
Gene transfer (and potential therapy)
CNS/neurodegenerative disease, 506
Parkinson's disease, 188, 339
for molecular analysis of behaviour, 183–190
Genomic models of CNS organization, 526
Genomics, neural
honeybee, 513–514
zebrafish retina, 539–540
Gephyrin, 429–435
Germinal neuroepithelium/matrix (ventricular zone), *see* Ventricular zone
Giant synapse, squid, 507–508(BR)
gigas, 558, 559
GIRK2, 395
Glia
cell cultures, cannabinoid receptors, 18
neurone and
ascorbate compartmentalization between, 212–213
ATP and extracellular signalling between, 625–632
radial glial fibres and Wulst (avian pallium) evolution, 4–5
serine protease effects, 401–404
Glutamate
ascorbate and, 211–212
dendritic spine morphology and, 54–55
excitotoxicity, mitochondrial Ca^{2+}, 167
Parkinson's disease and, 120
presynaptic effects of kainate on release of, 583–586
ventral striatum and, 383–384
Glutamate receptors
early-phase LPT and, 70–75
metabotropic, intracellular Ca^{2+} stores and ion channels and, 80–88
neurodegeneration and, selective, 365–371
seizures and GluR5/GluR6-containing kainate receptors, 582–583
see also specific types
Glutathione (GSH) and ascorbate, 214
Glycation products, advanced, in diabetes, 546, 547
Glycine receptors, postsynaptic, clusters, formation, 429–431
Goal-directed behaviour, motivation and, 414–415
Golgi, Camillo, 230–231(BR)
Gonadal steroids, seasonal changes in songbird brain and, 255–256
Grafts, cell (in nerve injury and degenerative disorders), 91–92
Gray, George, EM observations of synaptic structure in cerebral cortex, 594–598
Growth/outgrowth/sprouting and pathfinding/guidance/migration (of neurite/axon), 547–565
cortical neurones, 126–131, 530(L)
disorders, genetic and developmental mechanisms, 352–359
serine protease effects, 401–402
Growth cones and axonal branching, 557–564
Guillain–Barré syndrome (GBS), 317, 319, 320, 321

H
Haemolymph, opioid degradation, 553
Hair cells, 233–234, 386
Hcrt, *see* Hypocretins
Hearing, 233–234
fish and amphibian, 377–378(BR)
loss, *see* Deafness
Heart
muscle, channelopathies affecting, 395–396
nervous input, 449
Helicase deficiencies, 420, 421
Hepatolenticular degeneration (Wilson's disease), mitochondrial dysfunction, 300
Hereditary spastic paraplegia, 300
HERG, 396, 397
Herpes simplex virus for neuronal gene transfer, 183–190
Heterotopia, periventricular, 353
High vocal centre, neostriatal (songbird), 252–256
Hippocampus
AMPA and kainate receptors and selective neurodegeneration and, 366, 367
arbitrary visuomotor mapping and, 271–276
diabetes and, 544–545
ER and Ca^{2+} signalling and, 225
G-protein-independent signalling by G-protein-coupled receptors in CA3 pyramidal cells, 469, 472
kainate and seizures and, 580–587
LTP in (in CA1 region)
metabotropic Glu receptors and Ca^{2+}, 82, 86
postsynaptic protein phosphorylation and, 75–80
neuronal survival (in brain injury), CREB and, 48–53
pyramidal cells, *see* CA1; CA3; Pyramidal cells
synapses
crosstalk, 12–13(L)
facilitation/augmentation/potentiation, 305–312
Histocompatibility antigens (MHC) and neural xenograft rejection, 340–341, 342, 343
History of neuroscience, 147–151, 230–231(BR)
brain organization/architecture, 519–527
HLA (human MHC) and neural xenograft rejection, 340–341, 342, 343
Homeobox/homeotic genes
amniote expression patterns, interspecies comparisons, 2–3
corticogenesis and, 128
Emx, and mouse brain development, 347–352
Homeostasis, impaired, in neurodegenerative diseases, 602, 603–604
Homer proteins, 82, 85
Honeybee behaviour, 513–514
Hormones
nervous system interactions with, 329–330(BR)
sex differences relating to cognition, 138(BR)
HSV for neuronal gene transfer, 183–190
Huntingtin (htt), 385, 387–392, 601

Huntington's disease, 239–245, 300–301, 385, 387–392
animal models, 507(BR)
creatine and, 511
developmental pathogenesis, 601–603
mitochondria and, 240, 300–301
transcriptional dysregulation, 387–392
5-Hydroxytryptamine (serotonin)
crayfish proprioception and, 203
honeybee behaviour and, 513
5-HT_1 autoreceptors and dorsal raphé nucleus, 459–465
5-HT_3 receptors, and neurotransmitter release in CNS, 605–610
paracrine transmission involving, 58–59(L)
Hyperexcitability, neuronal, serine proteases and, 402–404
Hyperglycaemia and the brain, 546
Hyperinsulinaemia and cognition, 548
Hyperkalaemic periodic paralysis, 396–397
Hypocretins (Hcrt), 359–365
narcolepsy and, 362, 512
Hypothalamus
IL-1 and, 619, 621
oxytocin neurones, plasticity at GABAergic synapses of, 190–195
posterior, sleep and arousal state control and, 262
Hypoxic–ischaemic injury in hippocampus, CREB and neuronal survival following, 48–49

I

ICAD (inhibitor of caspase-activated deoxynuclease), 293
IGF1 and life and death signals, 176–178, 466(L)
Imaging, *see* Neuroimaging
Immune–nervous system interactions, *see* Neuroimmune processes
Immunization with β-amyloid, 114(L)
Immunoadhesins, 236–239
Immunological barriers to xenotransplantation for CNS repair, 337–343
In situ end-labelling plus (ISEL+), 407–409(L)
Infection, viral, *see* Viral infection
Inflammation
cytokines and neurodegeneration and, 175–180
neurogenic, pain and, 377(BR)
Information processing, 277–278(BR)
in blindness/deafness, perceptual advantage or disadvantage, 118
vision, 497–503, 571–579, 589(BR)
compared with pain processing, 588(BR)
Inhibitor of caspase-activated deoxynuclease, 293
Inhibitory postsynaptic receptor clusters, 429–435
Injury/trauma, neurological
ATP release in, 630–632
brain, *see* Brain
spinal cord, creatine and, 511
Inositol 1,4,5-triphosphate: Ins(1,4,5)P_3 (IP_3)
Ca^{2+} stores in neurones and, 80–88
receptors
chromogranins and, 424–428
ER and, 225
striatal projection neurones and, 123
transient receptor potential channels and, 163
Insect olfaction, 379(BR)
Insulin, brain and, 547–548
Insulin-dependent (type 1) diabetes mellitus, 543
Insulin-like growth factor-1 and life and death signals, 176–178, 466(L)
Interleukin-1, 618–624
in brain, 618–624
actions and sites and mechanism of action, 619, 621–622
expression, 618–619
neuroimmune responses and, 619
pathology, 619–621, 622
receptor(s), 620
receptor antagonist effects, 621
survival signals and, 178
Intermediate zone (IZ) of developing cortex, 127–131
Interneurones
assistance reflex, 203
cortical, origin/migration, 126–131, 530(L)
GluR5-containing receptors on, kainate and seizures and, 582–583
oriens-lacunosum moleculare, 311
striatal cholinergic, 122
Ion channels, 442–443(BR)
Ca^{2+} and metabotropic Glu receptors and, 80–88
defects (channelopathies), 442–443(BR)
epilepsy and, 393–398
ligand-gated, 5-HT_3 receptor, 605–610
TRP (transient receptor potential), 159–166
voltage-gated, noise generated by, 131–137
see also specific types of channels
Iron oxide, biogenic (=magnetite), 156
Ischaemia
cerebral, ascorbate and, 213–214
limb, paraesthesia and, 515–516
Ischaemic brain damage/ischaemic stroke
neuroprotective drug trials, 245–246(L)
serine proteases and, 404–405
Ischaemic stroke, neuroprotective drug trials, 245–246(L)
Isocortex, *see* Neocortex

J

JNK, 261, 262–263

K

Kainate
receptors, Ca^{2+}–Zn^{2+} permeable, and selective neurodegeneration, 365–371
seizures and, 580–587
KCNA1 K^+ channel, 395
KCNJ6 K^+ channel, 395
KCNQ K^+ channels, 442
epilepsy and, 393–398
Knockout/null mutants
cell death in CNS/retina, 484
Emx2, 350
Oprm1, 437
Kuz (Kuzbanian), 592

L

L-type Ca^{2+} channels, ryanodine receptors and metabotropic Glu receptors and, 81–83
Lactation and plasticity at GABA synapse of oxytocin neurones, 191, 193–194
Lambert–Eaton myasthenic (LEMS) syndrome, 317, 319, 320, 321, 323
Laminin and Duchenne muscular dystrophy, 94, 96
Language, evolution, 276
Lateral line placode, 314
Learning, 271–276, 444–445(BR)
diabetes and, 545
drug-associated, 384
honeybee, 513
motor, conditional, 271–276
ventral striatum and, 383–384
Leber's optic atrophy, 300
Lens (ophthalmic/trigeminal) placode, 314, 315
Leptin and IL-1, 619
Lhx6, 128
ligand-gated ion channels, 5-HT_3 receptor, 605–610
Ligase IV, 100–102
LIM homeobox gene (*Lhx6*), 128
Limb-girdle muscular dystrophy, 94, 95, 97
Limb ischaemia and paraesthesia, 515–516
Limb movement
forelimb, *see* Forelimb movement
pulvinar nuclei and, 37
Limbic system and negative symptoms/apathy, 413, 415
Lipid-anchored gephyrin interaction partners, 431–432
Lipid mediators and astrocytoma cell transcriptional programmes, 259–264
LIS1/Lis1, 353–354, 357
Lissencephaly, 353–354
type II, 357
Lizards, cortical development, 634, 636, 637
Locomotor systems, crayfish, stretch reflex and, 199–208
comparisons with humans, 528–530(L)

Long-term depression (LTD), Ca^{2+} and, 55
ER and, 225
metabotropic Glu receptors and, 86
neurotrophins and, 643
ventral striatum and, 383
Long-term potentiation (LTP)
amygdala and, 345–346(L)
Ca^{2+} and, 55
ER and, 225
metabotropic Glu receptors and, 82, 86
corticostriatal, ACh and muscarinic receptors, 123–124, 124
diabetes and, 544–545
in motor systems, 207
neurotrophins and, 643
postsynaptic protein phosphorylation and, 75–80
ventral striatum and, 383
Long QT syndrome, 394, 396, 397, 443
Long transient receptor potential channels (LTRPC), 161, 164, 165
Lrp8, 356
LTD and LTP, *see* Long-term depression; Long-term potentiation

M

M-current and seizures, 393–394
M1 and avian pallium, comparisons, 9–10
Mcl1 and CREB-induced neuronal survival, 51
MAGE family, 591
Magnetite, biogenic, 156
Magnetoreception, vertebrates, 153–159
Major histocompatibility complex and neural xenograft rejection, 340–341, 342, 343
Malonic acid, 329(BR)
Malpighi's observations on brain anatomy/organization, 521, 522
Mammals, cortical development, 634, 635, 636, 637
Map(s)/atlases/topography (brain/cortex etc.)
cortical (representation) map plasticity in stroke recovery, 266–267, 269
humans, 89(BR)
rat brain, 88–89(BR)
MAP kinase, *see also* Mitogen-activated protein kinase
Marginal zone (MZ) in cortical development, 126–131, 633–638
Math-1, 386
Mathematical theory in neuroscience, social barriers, 334–336
Mechanotransduction in audition, 233
Medial cortex in evolution, 634
Medulla oblongata and vagal axons, 449
Melanoma antigen family (MAGE), 591
Membrane, postsynaptic, formation, 429–435
Membrane potential
mitochondrial, excitotoxicity and, 166–174
neurotransmitter release and, 60–68
Memory
amygdala and, 345–346(L)
CREB and, 52
in diabetes, 544
episodic
frontal lobe activation foci, 480–481
and retrosplenial cortex, 197(L)
honeybee, 513
perceptual, vision and, 247–251
working, frontal lobe activation foci, 477–478
Mental illness, *see* Psychiatric illness
Mesencephalon, ventral, transplantation in Parkinson's disease, 91–92, 337
pig donor, rejection, 339–340
Metabotropic receptors
for ATP, *see* P2Y receptors
G-protein-independent signalling, 469–475
MAP kinase activation and, 470–472
metabotropic Glu receptors and ion channels and intracellular Ca^{2+} stores, 80–88
Mexiletine, 396–397
MHC and neural xenograft rejection, 340–341, 342, 343
Mice, *see* Mouse
Microtubules and axonal branching, 559–560, 561
Mind, 229–230(BR)
MiRP1, 396
Mitochondria, 298–304, 329(BR)
in apoptosis, 486–487
excitotoxicity/neurotoxicity and, 166–174
Huntington's disease and, 240
NMDA receptors and, 366
neurodegenerative disease and, 240, 298–304, 329(BR)
Mitogen-activated protein kinase (MAP kinase; MAPK)
astrocytoma cell transcriptional programmes and, 259–264
metabotropic receptors and, 470–472
retinal ganglion cell apoptosis/survival and, 489
Molecular embryology, methods/protocols, 380–381(BR)
Molybdenum cofactor biosynthesis, 432
Monoclonal antibodies targeting proteins, 238
Monoclonal gammopathy-associated neuropathy, 320, 321
Morphine, endogenous, 436–441
Mossy fibre synapses on CA3 pyramidal neurones, kainate and seizures and, 582
Motility, cell, actin and, 142–144, 144–145
Motivation, 384
goal-directed behaviour and, 414–415
Motoneurones and crayfish locomotion, 204–206
Motor cortex
avian pallium homologies with areas in, 9–10
visual area connections to, for sensory guidance of movement, 613–617
Motor learning, conditional, 271–276
Motor neuropathy, multiple (MMN), 320, 321
Motor systems, 41(BR)
in stroke recovery, resembling development, 265–266
see also Locomotor systems
Mouse brain development
cortical development, 635, 636, 636–637
Emx homeogenes and, 347–352
migration defects in human and, 357
Movement
eye, pulvinar nuclei and, 37
limb, *see* Limb movement
visuo–motor control and sensory guidance of, 613–617
Multiple motor neuropathy (MMN), 320, 321
Multiple sclerosis
autoantibodies and, 317, 319, 320, 321, 322, 323
IL-1 and, 622
see also Demyelinating diseases
μ-opiate receptor and endogenous morphine, 436–441
Murine brain development, *see* Mouse
Muscarinic ACh receptors
astrocytoma cell transcriptional programmes and, 260
G-protein-independent signalling, 469
metabotropic Glu receptors and, 82, 84
striatal, 121–124
Muscle, skeletal and cardiac, in channelopathies, 395–396
Muscular dystrophy, 92–99
Becker, 92, 93
Duchenne, 92–99
limb-girdle, 94, 95, 97
other, 97
Mutagenesis in zebrafish, 536, 539–540
Myasthenia gravis (MG), 319, 320, 321, 323
Myelin, axonal oscillations and peripheral loss of, 517–518
Myotonias and channelopathies, 396–397

N

Narcolepsy, orexins and hypocretins and, 362, 512
Natural killer cells in neural xenograft rejection, 339, 340, 341, 343
Necrosis/necrotic death (neuronal primarily), 410–411
apoptosis vs, 410–411
calpain in, 21
diagnostic markers, 22
in neurological/neurodegenerative disorders, 20–21

Negative symptoms (neurological and psychiatric disorders), 412–417
Neocortex (isocortex), mammalian
avian pallium homologies with, 1–12
synapses, facilitation/augmentation/potentiation, 305–312
tangential migration of neurones into, 129
Neonatal convulsions, benign familial (BFNC), 393, 394, 396
Neostriatal high vocal centre of songbirds, seasonal plasticity, 252–256
Nerve growth factor (NGF), 591
developmental cell death and, 487
in transduction of neuronal survival signals, 593
Neural crest in development and evolution, 445–446(BR)
Neuroactive steroids, 57–58(L), 138–139(BR)
Neuroanatomy of rat brain, 88–89(BR)
Neuroblast death in early development, 455
Neurocomputational studies, *see* Computational studies
Neurodegeneration (and neurodegenerative disorders), 175–180, 239–245, 298–304, 329(BR), 365–371, 417–424, 466–467(L), 506–507(BR), 599–604
AMPA and kainate receptors and selective neurodegeneration, 365–371
animal models, 506–507(BR)
Ca^{2+} signalling in ER and, 226–227
cell death in, 599–604
in Huntington's disease, 239–245
necrotic, 20–21
cytokines, 175–180, 466–467(L), 619–621, 621, 622
DNA damage and, 417–424
genes involved, *see* Genes
mitochondria and, 240, 298–304, 329(BR)
TNFα and, 175–180, 466–467(L)
Neuroendocrinology, 329–330(BR)
Neuroepithelium, germinal, *see* Ventricular zone
Neurofilament(s), George Gray's EM observations, 597
Neurofilament-light genes and Charcot–Marie–Tooth disease, 385
Neurogenesis
neurodegenerative disease and, 601
retina, *see* Retina
Wulst (avian pallium) lamination and evolution and, 5–6
see also Development
Neurogenic inflammation and pain, 377(BR)
Neurogenic placodes, *see* Placodes
Neurogenomics, *see* Genomics
Neuroimaging
Alzheimer's disease, new techniques, 386
functional
and emotional processes, 195–197(L)
frontal lobe, 475–483
Neuroimmune processes
B cell and immune response in CNS, 323–324
IL-1 and, 619
opiates/opioids and, 437, 439, 550–555
Neurological disorders
autoantibodies in, 317–326
necrotic cell death in, 20–21
negative symptoms, 412–417
Neuromodulation (and neuromodulators), 277–278(BR)
ascorbate role, 214
honeybee, 513
proprioceptive, in crayfish, 203
Neuromuscular junction
Duchenne muscular dystrophy and, 94, 95
neurotrophin secretion, 641
synaptic remodelling, 333
Neuromyotonia, acquired (aNMT), 319, 320, 321
Neurone(s)
behavioural studies via gene transfer into, 183–190
channel noise, 131–137
connections between, 333
see also specific areas/structures
death and survival, *see* Apoptosis; Death; Survival
development, *see* Development
diversity, DNA breaks and, 103–104
firing patterns, synchronization, 68–74
frequency preferences, 216–222
glia and, *see* Glia
growth/migration, *see* Growth
injury, reaction, 91
ion channels and intracellular Ca^{2+} stores and metabotropic Glu receptors in, 80–88
molecular and cellular physiology, 180–181(BR)
mosaics (non-random arrays)
extraretinal, 27
retina, 26–34
neurotrophin expression and secretion regulated by, 639–640
oscillatory, *see* Oscillations
plasticity, *see* Plasticity
postmitotic and differentiating, DNA breaks in, 100–105
resonance in, 216–222
serine protease effects, 401–404
survival, *see* Survival
see also Axon; Dendrites; Interneurones; Motoneurones; Sensory neurones
Neuropathy
diabetic, encephalopathy and, links, 546
monoclonal gammopathy-associated, 320, 321
Neuropeptides
definition, 113–114(L)
immune system and opioids, 437, 439, 550–555
Neuroprotection
ascorbate and, 209–216
CREB and, 48–53
in ischaemic stroke, clinical trials, 245–246(L)
TNFα and, 467
Neuropsychological studies, diabetes, 542, 543
Neuroscience
Elsevier's Encyclopedia, 139–140(BR)
European, FENS 1st winter school, 91–92
functional, 647(BR)
history, *see* History of neuroscience
PhDs, 4-year, 280–283
research techniques, 231(BR)
student textbook, 41–42(BR)
theoretical, social barriers, 334–336
Neuroscion, 510
TINS availability, 279
Neurosteroids, 57–58(L), 138–139(BR)
Neurotoxicity of dopamine, 239–245
see also Excitotoxicity
Neurotransmission, 277–278(BR)
cholinergic, striatal, 120–126
LTD, *see* Long-term depression
LTP, *see* Long-term potentiation
neurotrophins and activity-induced modification of, 639–645
paracrine mode (volume transmission), 58–59(L)
squid giant synapse as model for, 507–508(BR)
Neurotransmitters
autoreceptors, *see* Autoreceptors
in developing fetus, cannabinoid effects, 15
honeybee, 513
K^+ channels and, 234–235
regulation of/influences on release, 60–68, 305–312
glial receptors, 626–627
5-HT_3 receptors, in CNS, 605–610
release probability, 305–312
Neurotrauma, *see* Injury
Neurotrophic factors in development and cell death, 454, 487–488
Neurotrophic viruses and neural cell suicide, 284–290, 467–468(L), 611–612(L)
Neurotrophin(s) (NTs)
in apoptosis
in development, 487–488
in lesioned CNS, 488
p75 receptor, *see* p75 neurotrophin receptor
synaptic plasticity and, 639–645
targeting with immunoadhesins, 239
Neurotrophin-receptor interacting MAGE homologue, 591–592

NF-κB
apoptosis and, 466
astrocytoma cell transcriptional programmes and, 260–262
ER and, 225
morphine and, 439–440
NF-L genes and Charcot–Marie–Tooth disease, 385
NGF, *see* Nerve growth factor
Nijmegen breakage syndrome, 419
Nitric oxide (NO)
Duchenne muscular dystrophy and, 96
morphine and, 439–440
3-Nitropropionic acid, 329(BR)
Nkx2.1, 128
NMDA receptors
agonists/antagonists in stroke, 268–269
diabetes and, 545
Huntington's disease and, 240, 243
LTP and
early-phase, 75–76, 79
metabotropic Glu receptors and, 86
mitochondria and neurotoxicity and, 366
serine proteases and, 403, 405
striatal, 122–123
NO, *see* Nitric oxide
Non-insulin-dependent (type 2) diabetes mellitus, 543
brain and, 548
Noradrenaline release and 5-HT_3 receptors, 608
Novel tasks, frontal lobe activation foci, 477, 478
NRAGE, 591–592
NRIF (neurotrophin receptor interacting factor) and developmental cell death, 487
Nuclear factor-κB, *see* NF-κB
Nucleotide(s), 277(BR)
excision repair deficiencies, 419–420
receptors, 277(BR)
Nucleus, cell, huntingtin and, 388–390
Nucleus accumbens and cocaine abuse, 186–188
Nucleus ambiguus and vagal axons, 449
Nucleus of basal optic root, pigeons, 155
Null mutants, *see* Knockout mutants

O

Occipital cortex in blindness, cross-modal reorganization, 115–120
Ocular dominance column, 643
Oedema (brain), thrombin-induced, 402
Oestrogen synthase in brain, 57(L)
Olfaction, insect, 379(BR)
Olfactory glomeruli, honeybee, 513
Olfactory placode, 314, 315
Oligodendrocyte–neurone communication and ATP, 626, 630, 632
Oligonucleotides, antisense, *see* Antisense oligonucleotides
On-line availability, *TINS*, 279
Ontogeny, *see* Development
Ophthalmic (trigeminal) placode, 314, 315
Opioids/opiates
in analgesia, 181–182(BR), 437
endogenous, 436–441
neuroimmune processes and, 437, 439, 550–555
receptors, 436–441
types, 437
Opium, 436
Oprm1, 437
Opsins and retinal mosaics, 28–29
Optic (ophthalmic/trigeminal) placode, 314, 315
Orexins, 359–365
narcolepsy and, 362, 512
Oriens-lacunosum moleculare interneurones, 311
Oscillations/rhythms (and oscillatory neurones), 216–222
channel noise and, 134–135
oscillating axons and demyelinating disease, 517–518
Osm-9-like transient receptor potential channels (OTRPC), 161, 162, 163–165
Otic placode, 314, 315, 332
Oxford University 4-year neuroscience PhD, 281–282, 283
Oxidative stress/damage
Alzheimer's disease and, 302
Huntington's disease and, 240, 241
Oxygen radical scavenger, ascorbate as, 214
see also Antioxidants
Oxytocin neurones, plasticity at GABAergic synapses of, 190–195

P

P1 receptors, 631
P2X receptors, 277(BR)
neurone–glial signalling and, 627
P2Y receptors (metabotropic receptors), 277(BR)
neurone–glial signalling and, 627
p35 (=Cdk5r2), 356–357, 357
p55 TNF receptor, 177, 178, 179
p75 neurotrophin receptor, 591–592
cell death and, 487, 501
p75 TNF receptors, 177, 178, 179
PAFAH1β1 (*Lis1*), 353–354, 357
Pain
amygdala and, gene transfer studies, 188
management, novel aspects, 181–182(BR)
see also Analgesia
neurogenic inflammation and, 377(BR)
psychological mechanisms, 587–588(BR)
Pallium, *see* Cortical areas
Paracrine neurotransmission, 58–59(L)
Paradoxical sleep, 140(BR)
Paraesthesia and limb ischaemia, 515–516
Paramyotonia congenita, 396–397
Paraneoplastic syndromes (PS), 320, 321
Paraplegia, hereditary spastic, 300
Parkinson's disease, 120–122
animal models, 506(BR)
autosomal dominant forms, 603–604
neural transplantation, 91–92, 337
therapy, 120
gene transfer studies, 188, 339
mitochondrial dysfunction in, 301
volume transmission and, 59(L)
Peptides, neuroactive, *see* Neuropeptides
Perception, visual, 42–43(BR), 498–499
colour vision, 589
frontal lobe activation foci, 478
Perceptual memory, vision and, 247–251
period, 513
Periodic paralysis, hyperkalaemic, 396–397
Peripheral nervous system
autoimmune disorders, 320
ectopic discharges, 514–519
Perireticular nucleus, 530
Periventricular heterotopia, 353
Permeability transition pore, mitochondrial membrane, 167
PhDs in neuroscience, 4-year, 280–283
Phosphatidylinositol 3′ kinase
postsynaptic inhibitory receptor clustering and, 433, 434
survival signals and, 176–177, 178, 179, 466(L), 593
Phospholipase A_2, cytosolic, astrocytoma cell transcriptional programmes and, 259–264
Phospholipase C and transient receptor potential channels, 161–162
Phosphorylation (protein)
CREB, 50
postsynaptic, LTP and, 75–80
Photoreception, 588(BR)
colour vision and, 589(BR)
in compound eye, polyunsaturated fatty acids and, 13–14
Photoreceptors
chemical magnetoreception in, 155–156
in development
mosaic patterns, 26–34
zebrafish, 531–541
see also Cones; Rods
Pial limiting membrane and type II lissencephaly, 357
Pig donor tissue in CNS repair, 337–343
Pigeons, magnetoreception, 155
Pineal gland and magnetoreception, 155
Placodes, neurogenic, 313–316
otic placode, 314, 315, 332
Plasma, opioid degradation, 553

Plasticity (in nervous system/neuronal)
Ca^{2+} signalling in ER and, 222–229
cortical-map, in stroke recovery, 266–267, 269
cross-modal, 115–120
dendritic spine morphology and, 53–57
drug-associated, 384
honeybee brain, structural plasticity, 513
postsynaptic $GABA_A$-receptor, 190–195
seasonal, adult brain, 251–258
synaptic, *see* Synapse
Poly(ADP) ribose polymerase as caspase substrate, 23
Polyglutamine-containing proteins, 601–603
huntingtin as, 387–388
Polyunsaturated fatty acids and compound eyes, 13–14(L)
Pontine nuclei
and cerebro-cerebellar communication, 152–153(L)
and visuomotor connections in sensory guidance of movement, 615–616
Porcine donor tissue in CNS repair, 337–343
Positron emission tomography, functional frontal lobe imaging, 476
Posterior cingulate cortex, *see* Cingulate cortex
Postsynaptic sites
$GABA_A$-receptors, *see* $GABA_A$-receptor
$5\text{-}HT_3$ receptors, 605, 607
inhibitory receptor clusters, 429–435
neurotrophins
effects, 642
secretion, 640–641
protein phosphorylation, LTP and, 75–80
Potassium ion channels and currents, 234–235
epilepsy and, 393–398
KCNA1, 395
KCNJ6, 395
KCNQ, *see* KCNQ
metabotropic Glu receptors and Ca^{2+} and, 82, 83–84
peripheral nerve ectopic activity and, 514–519
striatal, 121
TASK, 234–235
Precursor cells, neural, proliferating, early death, 455
Prefrontal cortex, functional specializations within, 475–483
Pregnanolone sulphate, 139(BR)
Pregnancy
fetus in, *see* Fetus
and plasticity at GABA synapse of oxytocin neurones, 191, 193–194
Preplate, 352
reeler mouse, 355
Presenilin-1
ER-mediated Ca^{2+} signalling and, 226
neurodegenerative disease and developmental signalling networks and, 601, 603
Presynaptic effects/role
$5\text{-}HT_3$ receptors, and neurotransmitter release in CNS, 605–610
kainate, 583–584
neurotrophins, 642
stretch reflex and presynaptic inhibition in sensory/afferent axons, 201–202, 528(L)
Presynaptic secretion of neurotrophins, 640–641
Primate pulvinar nuclei, *see* Pulvinar nuclei
Prions, 182(BR)
Proencephalon, *see* Forebrain
Proenkephalin-derived peptides and neuroimmunity, 552, 554
Progenitor cells, neuronal, apoptosis, 296
Prohormone/pro-protein convertases in neuroimmunity, 551–552, 553
Proopiomelanocortin-derived peptides and immunity, 552
Proprioception, crayfish, 203–206
Pro-protein/prohormone convertases in neuroimmunity, 551–552, 553
Prosencephalon, *see* Forebrain
Protease(s)/proteinases
amyloid precursor protein-processing, 565–570
brain damage/neuronal death and, 20–26, 399–407
see also specific (types of) proteases
Protease-activated receptors (PARs), 399–400, 401–402
Protease nexin (PN1), 400–401, 402, 403
Protein(s)
phosphorylation, *see* Phosphorylation
processing impairment, and neurodegenerative disease, 603–604
targeting, 236–239
Protein kinase A and early-phase LTP, 78
Protein kinase B and apoptosis, 488–489
Protein kinase C
as caspase or calpain substrate, 24
early-phase LTP and, 78
Protein phosphatases during early-phase LTP, regulation, 78
Proteinases, *see* Proteases
Protonmotive force, mitochondrial, 167–174
Psychiatric/mental illness
negative symptoms, 412–417
neurobiology, 505–506(BR)
Psychological mechanisms of pain and analgesia, 587–588(BR)
Psychophysics, 42–43(BR)
Psychosocial stress, 333
Pulvinar nuclei, primate, 35–39
action and, 37–38
structure/infrastructure, 35–36
vision and, 36–37
Purinergic receptors, 277(BR), 631
neurone–glial signalling and, 627
Purkinje cells, dendritic spine density, 198(L)
Pyramidal cells
excitatory (cerebral cortex), origin/migration, 126–131
hippocampal, AMPA and kainate receptors and selective neurodegeneration and, 366, 367
see also CA1; CA3

Q

QT interval, prolonged, 394, 396, 397, 443
Quantal-analysis techniques with synapses, 105

R

RAFT1, 431, 433, 434
Ramón y Cajal, 230(BR), 231(BR)
Rasmussen's encephalitis (RE), 320, 321
Rat brain, structure/maps, 88–89(BR)
Reaching movement and pulvinar nuclei, 37
Receptive fields of visual cortex, 497–503
Receptor kinase function, targeting, 236–239
Recognition, visual, 42–43(BR)
RecQ helicase deficiencies, 421
Recurrent processing in vision, 571–579
Reelin and reeler mouse, 349–350, 351, 355–356, 633–638
Reference frames and pulvinar nuclei, 38
Regeneration, CNS, 91
REM sleep, 140(BR), 362–364, 511
Repair
CNS, *see* Central nervous system
DNA breaks, 101
Representation, visual, 42–43(BR)
Reptiles, cortical development, 634, 635, 636, 637
Research, neuroscience
advice for young investigators, 327–328(BR)
PhD, 4-year, 280–283
techniques, 231(BR)
Resonance in neurones, 216–222
Response conflict, frontal lobe activation foci, 477, 478
Reticulum theory of brain cell communication, 68
Retigabine, 397
Retina, 26–34, 483–490
cell death (and survival), 483–490
in development, 32–33, 455, 456, 484–488, 591
with lesions, 488–489
colour vision and, 589(BR)
Duchenne muscular dystrophy and, 97, 98
neurogenesis
non-random arrays/mosaics, 26–34
zebrafish, 531–541

Retrosplenial cortex and emotions, 195–197(L)
Retroviruses
for neuronal gene transfer, 184
pig donor tissue-related risk of infection, 338
Rhythms, *see* Oscillations
robo, 561–562
Robust nucleus of archistriatum (RA) of songbirds, 252–256
Rods
multiple pathways, 39(*erratum*)
retinal mosaics and, 29–30
Romano–Ward (long QT) syndrome, 394, 396, 397, 443
Rothmund–Thomson syndrome, 421
Ryanodine receptors, Ca^{2+} stores/homeostasis and, 80–88
ER and, 225

S

S1, comparisons with Wulst (avian pallium), 7–9
Salience, visual, pulvinar nuclei and, 37
Sarcoglycans and Duchenne muscular dystrophy, 94, 95
Schizencephalies and EMX2, 350
Schizophrenia, negative symptoms, 413
Schwann cell–neurone communication, ATP-mediated, 626–631
Seasonal plasticity in adult brain, 251–258
Second messenger systems, *see* Signal transduction
β-Secretase, amyloid precursor protein processing, 565–570
Secretory granules, chromogranins, IP_3 receptors and, 424–428
Secretory vesicles, Ca^{2+}-dependent exocytosis, 43(*erratum*)
Segmental brain model, 520–521, 522–523, 524
Seizures/convulsions, epileptic
kainate and, 580–587
KCNQ K^+ channels and, 393–398
neuronal synchrony and, 68–74
serine proteases and, 402–404
Sensory cortex
avian pallium homologous areas, 1–12
cross-modal reorganization of function, 115–120
Sensory guidance of movement, visuomotor control and, 613–617
Sensory–motor organization, stretch reflex and, 199–208
Sensory neurones (and afferent axons)
anandamide as ligand for vanilloid receptors in, 493–494
stretch reflex and presynaptic inhibition in, 201–202, 528(L)
Sensory systems, 41(BR), 588–589(BR)
cranial, development, neurogenic placodes and, 313–316
cross-modal reorganization with sensory deprivation, 115–120
Serine proteases, 399–400
Serotonin, *see* 5-Hydroxytryptamine
Sex, cognition and, 138(BR)
Sex steroids, seasonal changes in songbird brain and, 255–256
Sexual differentiation, brain, 507(BR)
Short transient receptor potential channels (STRPC), 161, 161–163
Signal transduction (and second messenger systems)
astrocytoma cell transcriptional programmes and, 259–264
G-protein-coupled receptors, G-protein independent, 469–475
5-HT_1 receptors, 461
IL-1 receptor, 620
neuronal survival signals, 593
striatal projection neurones, NMDA and muscarinic receptors and, 122
transient receptor potential channels and, 161–163
Silencer of survival signals, 175–180
Six transmembrane segments, cation channels with, 160, 161
Skeletal muscle, channelopathies affecting, 395–396
Skilled forelimb movement, *see* Forelimb movement
Sleep
paradoxical, 140(BR)
REM, 140(BR), 362–364, 511
and sleep disorders, 359–365
slit, 561–562
Social barriers to theoretical neuroscience, 334–336
Social behaviour, voles, 452, 453
Sodium ion channels defects in muscle, 396–397
Sodium ion currents and ectopic activity in peripheral nerves, 514–519
Sodium ion-dependent vitamin C transporters, 213
Somatosensory cortex, avian pallium homologies with areas in, 9–10
Somatotopic mapping, plasticity in stroke recovery, 266–267, 269
Songbird brain, seasonal plasticity, 251–258
Sorcin, 226
Sound, occipital cortex in blindness activated by, 117
Spastic paraplegia, hereditary, 300
Spatial changes of cortical receptive fields, 500–501
Spectrins as calpain and caspase substrate, 22, 23
Spikelet recordings in studies of electrotonic transmission, 70, 71
Spinal cord
descending pathways, and skilled forebrain movement, 372–376
injury, creatine and, 511
volume (paracrine) transmission, 58(L)
Spines, dendritic, *see* Dendrites
Spongiform encephalopathies, transmissible, 182(BR)
Squid giant synapse, 507–508(BR)
SRC kinase signalling, 470–473
Stem cells, embryonic vs adult, 450
Stereocilia, 233–234
Stereotaxic surgery, immunoadhesins delivered by, 237
Steroids
gonadal, seasonal changes in songbird brain and, 255–256
neuroactive, 57–58(L), 138–139(BR)
Stiff-person syndrome (SPS), 317, 319, 320, 321
Stimuli, visual, and receptive fields, 497–503
Stress, psychosocial, 333
Stretch reflex, crayfish, 199–208
comparisons with humans, 528–530(L)
Striatal cortex, receptive fields, 497–503
Striatum, 383–384
acetylcholine in, 120–126
archistriatal and neostriatal regions of songbird, seasonal plasticity, 252–256
in Huntington's disease, vulnerability, 239–245
negative symptoms and apathy and, 413
ventral, 383–384
Stroke
ischaemic, neuroprotective drug trials, 245–246(L)
recovery recapitulating ontogeny, 265
Stroop effect, 477
Student textbooks in neuroscience, 41–42(BR)
Subplate, 352
Substance abuse, *see* Drug abuse
Subtilase-like pro-protein convertases in neuroimmunity, 551–552
Superoxide dismutase, Cu–Zn, and amyotrophic lateral sclerosis, 301
Survival (in CNS), 483–490
neuronal, 175–180, 593
Bcl2 family and, *see Bcl2*
CREB and, 48–53
phosphatidylinositol 3′ kinase and, 176–177, 178, 179, 466(L), 593
regulation in early neural development, 456–457
transduction of survival signals, 593
retinal cells, *see* Retina
see also Death; Silencer of survival signals

Synapses
central, facilitation/augmentation/potentiation, 305–312
in cerebral cortex, George Gray's EM observations of structure, 594–598
connections, 333
formation, 449
crosstalk in hippocampus, 12–13(L)
glial receptors for vesicular release of neurotransmitters, 626–627
mossy fibre, on CA3 pyramidal neurones, kainate and seizures and, 582
plasticity/re-modelling, 380(BR)
cholinergic striatal system and, 124, 125
diabetes and, 542–549
at GABAergic synapse of oxytocin neurones, 190–195
graphical and analytical approaches to, 105–113
metabotropic Glu receptors and, 82
at neuromuscular junction, 333
neurotrophins and, 639–645
in songbird robust nucleus, seasonal, 254
silent, and early-phase LTP, 78–79
squid giant synapse, 507–508(BR)
stability of, dendritic spine motility and, 145
visual stimulation and receptive fields and, 499–500, 500
see also entries under Presynaptic; Postsynaptic
Synchronization of neuronal firing patterns, 68–74
Syntrophin and Duchenne muscular dystrophy, 95, 96
α-Synuclein, 603

T
T cells
immunization with β-amyloid and, 114(L)
in neural xenograft rejection, 340–342
Tangential movement/migration
nonpyramidal (cortical interneuronal) cells to cortex, 128, 129
retinal cells, 30–32
TASK, 234–235
Task novelty, frontal lobe activation foci, 477, 478
Tau as calpain or caspase substrate, 23
Tauc, Ladislav, 47(O)
Tegmentum, ventral, negative symptoms and apathy and, 413
Telencephalon, amniote comparisons, 634
homeotic gene expression, 2
laminar inputs and outputs, 3
Temporal changes caused by synaptic processes, 499–502
Temporal lobe epilepsy
inhibition, fate, 585
kainate animal model, 580–582
Teratogen, alcohol as, 40–41(BR)
Testosterone and seasonal changes in songbird brain, 255–256
Thalamus
negative symptoms and apathy and, 413, 415
pulvinar nuclei, *see* Pulvinar nuclei
Theoretical neuroscience, social barriers, 334–336
Theta activity, 311
Thrombin (and thrombin receptors)
astrocytoma cell transcriptional programmes and, 260–262
neuropathological role, 399–407
TNF, *see* Tumour necrosis factor
Tolerance, opiate, 440
Tonic block of neurotransmitter release, 65
depolarization-induced relief, 65–66
Torpedo and Alessandro Volta, 148
TRAAK K^+ channels, 234
Transcription
in astrocytoma cells, cytosolic phospholipase A_2 and, 259–264
CREB and regulation of, 48
DNA repair coupled to (TCR), 419
defects, 420
dysregulation in neurodegenerative diseases, 601, 602, 603–604
in Huntington's disease, 387–392
Transcription factors, apoptosis-related, 288
virus-encoded, 285
Transgenic mice, cell death in CNS/retina, 484
Transient receptor potential channels, 159–166
Transmembrane segments, six, cation channels with, 160, 161
Transmissible spongiform encephalopathies, 182(BR)
Transmission and transmitters, *see* Neurotransmission; Neurotransmitters
Transplantation/graft, cell/tissue (in nerve injury and degenerative disorders), 91–92
xenogeneic, immunological barriers, 337–343
Trauma, *see* Injury
Trichothiodystrophy, 420
Trinucleotide (triplet) repeat diseases, 601–603
see also CAG repeat
Triplet repeat diseases, *see* Trinucleotide repeat diseases
Trisomy 21 (Down's syndrome) and the DNA sequence, 332
TRP (transient receptor potential) channels, 159–166
Tubulin-binding protein (gephyrin), 429–435
Tumour necrosis factor (TNF)
developmental cell death and, 487
TNFα
arachidonate metabolism and, 262–263
neurodegeneration and, 175–180, 466–467(L)
Turtle, cortical development, 634, 635, 636, 637
2P K^+ channels, 234, 235
Tyrosine hydroxylase
endocannabinoids and, 15
Parkinson's disease and, 188
Tyrosine kinases
early-phase LTP and, 75–76
SRC family, signalling, 470–473

U
Ubiquitin carboxyl-terminal hydrolase mutations, 603–604
Ultraviolet-sensitive-syndrome, 420
University College London, 4-year neuroscience PhD, 282–283
Utrophin and Duchenne muscular dystrophy, 95
UV-sensitive-syndrome, 420

V
V1 (primary visual cortex)
avian pallium compared with, 7–9
information processing and, 571–577
perceptual memory and, 247–248
Vaccination with β-amyloid, 114(L)
Vagus nerve connections, 449
Vanilloid(s)
heterogeneous actions, 491–492
receptors, 491–497
ligands, 492
Variance–mean analysis of synaptic behaviour, 105–113
Variolo's observations on brain anatomy/organization, 521, 522, 524
Vasopressin and social behaviour, 452, 453
Ventral mesencephalon, *see* Mesencephalon, ventral
Ventral striatum, 383–384
Ventral tegmental area and negative symptoms/apathy, 413
Ventricular ridge, dorsal, in cortical evolution, 634
Ventricular zone (VZ), germinal (germinal neuroepithelium), in cortical development, 126, 127, 128, 130
Emx homeogenes and, 347–349
neuronal migration disorders and, 352, 353
Vertigo, 40(BR)
Very low-density lipoprotein receptor gene, 356

Vesalian model of brain CNS/brain organization, 520, 522, 524
Vesicles
secretory, Ca^{2+}-dependent exocytosis, 43(*erratum*)
synaptic, glial receptors for neurotransmitter release from, 626–627
Vestibular system and vertigo, 40(BR)
VGF and stroke recovery, 269
Vimentin as calpain or caspase substrate, 23
Viral infection
neural cell suicide and, 284–290, 467–468(L), 611–612(L)
pig donor tissue risk, 338
Viral vectors for neuronal gene transfer, 183–190
Vision
colour, 589
information processing, *see* Information processing
perception and, *see* Perception; Perceptual memory
pulvinar nuclei and, 36–37
representation and recognition in, 42–43(BR)
Visual cortex, 7–9, 497–503, 571
avian pallium homologies with areas in, 7–9
primary, *see* V1
processing, *see* Information processing
receptive fields, 497–503
sensory guidance of movement and, 613–617
Visual system, anatomical organization, 572
Visuomotor control and sensory guidance of movement, 613–617
Visuomotor mapping
arbitrary, 271–276
standard, 276
Vitamin C (ascorbate/ascorbic acid)
Alzheimer's disease and, 302
in CNS, 209–216
Vitamin E and Alzheimer's disease, 302
Vldlr, 356
Vole social behaviour, 452, 453
Volta, Allesandro, 147–151
Voltage-gated ion channels, noise generated by, 131–137
Voltaic battery, bicentennial, 147–151
Volume transmission, 58–59(L)

W
Wakefulness, orexins and hypocretins and, 359–365
Walking and stretch reflex, 528(L)
Werner syndrome, 421
White matter, cannabinoid receptors, 16–18
Willis's observations on brain anatomy/organization, 521, 522
Wilson's disease, mitochondrial dysfunction, 300
Working memory, frontal lobe activation foci, 477–478
Wulst (avian pallium) and mammalian counterparts, 1–12

X
X chromosome-linked lissencephaly, 354
Xenotransplantation for CNS repair, immunological barriers, 337–343
Xeroderma pigmentosum, 419–420
XRCC4, 100–102

Z
Zebrafish, retinal neurogenesis, 531–541
Zinc ions, AMPA and kainate receptors permeable to, selective neurodegeneration and, 365–371

Book Review Index

A

Abbott, L. and Sejnowski, J., ed., *Neural Codes and Distributed Representations: Foundations of Neural Computation*, 443

Adelman, G. and Smith, B.H., ed., *Elsevier's Encyclopedia of Neuroscience*, 139

Ashcroft, F.M., au., *Ion Channels and Disease*, 442

B

Baudry, M., Davis, J.L. and Thompson, R.F., eds, *Advances in Synaptic Plasticity*, 380

Baulieu, E-E., Robel, P. and Schumacher, M., eds, *Neurosteroids: A New Regulatory Function in the Nervous System*, 138

Bownds, M.D., au., *The Biology of Mind: Origins, Structures of Mind, Brain and Consciousness*, 229

Brain, S.D. and Moore, P.K., eds, *Pain and Neurogenic Inflammation*, 377

Brandt, T., au., *Vertigo: Its Multisensory Syndromes*, 40

Broman, S.H. and Fletcher, J.M., eds, *The Changing Nervous System: Neurobehavioural Consequences of Early Brain Disorders*, 504

C

Cajal, S.R., au., *Advice for a Young Investigator*, 327

Charnet, D.S., Nestler, E.J. and Bunney, B.S., eds, *Neurobiology of Mental Illness*, 505

Conn, M.P. and Freeman, M.E., eds, *Neuroendocrinology in Physiology and Medicine*, 329

E

Edelman, S., au., *Representation and Recognition in Vision*, 42

Emerich, D.F., Dean, R.L. III and Sanberg, P.R., eds, *Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic*, 506

F

Fay, R.R. and Popper, A.N., eds, *Comparative Hearing: Fish and Amphibians*, 377

Fain, G.L., au., *Molecular and Cellular Physiology of Neurons*, 180

G

Gegenfurtner, K.R. and Sharpe, L.T., eds, *Color Vision: From Genes to Perception*, 589

H

Hall, B.K., au., *The Neural Crest in Development and Evolution*, 445

Hanaway, J., Woolsey, T.A., Gado, M.H. and Roberts, Jr, M.P., eds, *The Brain Atlas: A Visual Guide to the Human Central Nervous System*, 89

Hannigan, J.H., Spear, L.P., Spear, N.E. and Goodlett, C.R., eds, *Alcohol and Alcoholism: Effects on Brain and Development*, 40

Hanson, B., ed., *Insect Olfaction*, 379

Hooper, N.M., ed., *Alzheimer's Disease: Methods and Protocols*, 446

I

Illes, P. and Zimmermann, H., eds, *Nucleotides and their Receptors in the Nervous System*, 277

J

Jouvet, M., au., *The Paradox of Sleep*, 140

K

Katz, P.S., ed., *Beyond Neurotransmission*, 277

Kimura, D., au., *Sex and Cognition*, 138

L

Leslie, R.A., Hunter, A.J. and Robertson, H.A., eds, *Antisense Technology in the Central Nervous System*, 447

Llinás, R.R., au., *The Squid Giant Synapse: A Model for Chemical Transmission*, 507

M

Matsumoto, A., ed., *Sexual Differentiation of the Brain*, 507

Mazzarello, P., au., *The Hidden Structure: A Scientific Biography of Camillo Golgi*, 230

Milner, P.M., au., *The Autonomous Brain*, 444

P

Price, D.D., au., *Psychological Mechanisms of Pain and Analgesia*, 587

Prusiner, S.B., ed., *Prion Biology and Diseases*, 182

R

Reggia, J.A., Ruppin, E. and Glanzman, D.L., eds, *Disorders of Brain, Behaviour and Cognition: the Neurocomputational Perspective*, 378

S

Sanberg, P.R., Nishino, H. and Borlogan, C.V., eds, *Mitochondrial Inhibitors and Neurodegenerative Disorders*, 329

Sawynok, J. and Cowan, A., eds, *Novel Aspects of Pain Management*, 181

Sharpe, P.T. and Mason, I., eds, *Molecular Embryology: Methods and Protocols*, 380

Smith, C.U.M., au., *Biology of Sensory Systems*, 588

Steward, O., au., *Functional Neuroscience*, 647

Stuart, G., Spruston, N. and Hausser, M., eds, *Dendrites*, 645

Swanson, L.W., au., *Brain Maps: Structure of the Rat Brain*, 88

T

Taylor, J., au., *The Race for Consciousness*, 648

W

Windhorst, U. and Johansson, H., eds, *Modern Techniques in Neuroscience Research*, 231

Z

Zigmond, M.J., Bloom, F.E., Landis, S.C., Roberts, J.L. and Squire, L.R., eds, *Fundamental Neuroscience*, 41